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Oncostatin M (OSM) is a pleiotropic cytokine that belongs to the interleukin-6 (IL-
6) family of cytokines. These cytokines play crucial role in diverse biological 
events like inflammation, neuroprotection, hematopoiesis, metabolism and 
development. For example, when exposed to moderate levels of oxidative stress 
(i.e. bright cyclic light), IL-6 family cytokines are strongly upregulated in the 
retina. Using inhibition studies, we show that these upregulated cytokines play an 
essential role in protecting the neuronal cells from succumbing to subsequent 
lethal doses of oxidative stress. These wide ranges of functions elicited by IL-6 
family cytokines are mediated by the formation of multimeric receptor complexes, 
which include a common receptor glycoprotein 130 (gp130). OSM is unique in 
this family since it can signal via two different receptor complexes i.e. 
LIFR:gp130 (type I) and OSMR:gp130 (type II). We have identified a unique 
helical loop on OSM between its B and C helices, which is not found on other IL-
6 family cytokines. Based on its size and location, we hypothesized that the BC 
loop is responsible for OSM’s unique ability to bind and activate OSMR. 
However, our experiments with mutated OSM molecules that have truncated BC 
loops showed that the BC loop does not play a role in OSM’s unique ability to 
bind OSMR, but instead presents a steric hindrance for OSM’s strong interaction 
with OSMR and LIFR. Kinetic and equilibrium binding analyses using surface 
plasmon resonance (SPR) and enzyme-linked immunosorbent assay (ELISA) 
support the evidence for improved binding and stability between mutant OSMs 
 xvi
and the receptor complexes. Also, as a consequence of improved binding, these 
structurally modified OSMs exhibit enhanced ability in suppressing the 
proliferation of A375 melanoma cells and also protecting the neuronal cells in 
retina from oxidative stress, demonstrating that improved binding has functional 
consequences. Finally, we have evaluated the applicability of poly(ethylene 
glycol) (PEG) based hydrogels for delivering these molecules in a controlled 
manner. Using in vitro and in vivo studies in mice, we show that PEG hydrogels 
fabricated with PEG-diacrylate macromers with a molecular weight of 5000 Da 
can be used to deliver these cytokines in a sustained manner for ~12 days. And, 
for transscleral transport, a release rate of at least 0.5 μg/day is required for OSM 





1.1. Oncostatin M and IL-6 family cytokines 
Human Oncostatin M (hOSM) is a pleitropic cytokine that belongs to the 
Interleukin-6 (IL-6) family of cytokines. It was originally isolated in 1986 from the 
growth media of phorbol 12-myristate 13-acetate (PMA) treated U-937 histiocytic 
lymphoma cells and identified by its ability to inhibit the growth of melanoma cell 
lines (1). OSM cDNA encodes for a 252 amino acid precursor protein, the first 25 
residues of which function as a secretory signal peptide which upon removal 
yields the soluble 227 amino acid pro-OSM (2). Cleavage of the c-terminal 31 
residues from this pro-OSM yields the fully functional mature OSM with 196 
residues and a molecular weight of 28 kDa (3) (Figure 1.1). This mature OSM 
contains two intra-molecular disulfide bonds (C6-C127 and C49-C167) resulting 
in the formation of a ‘four α-helix bundle’ like structure (Figure 1.2), a typical 
characteristic of the IL-6 family cytokines (4). In addition to tumor suppression, 
recent evidences have shown that OSM acts on a wide variety of cells in vivo 
and elicits diverse biological responses involved in inflammation, 
neuroprotection, haematopoiesis, tissue remodeling and development (5,6). 
 
1.1.1. IL-6 family Cytokines 
 
Cytokines represent a diverse group of small soluble proteins that when secreted 
by one cell can act on the same cell, in an autocrine fashion, or on another cell, 
in a paracrine fashion. Through binding to specific cell surface receptors, they 
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initiate signals that are critical to a diverse spectrum of functions including 
induction of immune responses, cell proliferation, differentiation, and apoptosis. 
The defining structural feature of the cytokine family is a ‘four-α-helix bundle’ like 
structure (7-9), which is composed of four amphipathic helices having solvent-
facing hydrophilic sides and hydrophobic sides that form the core of the helical 
bundle. These four helices are oriented into a unique ‘up-up-down-down’ 




Figure 1.1 Protein sequence of full length and mature human OSM 
Alpha helical regions in both sequences are highlighted in gray A) Full length 
hOSM consists of a 25 amino acid secretory signal peptide (shown in box) at the 
N-terminal. Cleavage of this secretory signal peptide yields pro-OSM. Cleavage 
of C-terminal 31 amino acids from this pro-OSM (shown with arrow) yields the 
fully functional mature OSM. B) Mature OSM consists of five cysteines (C6, C49, 
C80, C127,C167), four of which (C6-C127; C49-C167) (shown in boxes) 
participate in formation of disulfide bonds stabilizing the four-α-helix bundle like 





Figure 1.2 Crystal structure of mature human OSM with its N and C terminals 
indicated. 
Helices A, B, C and D are labeled in the picture while the cysteines (C6, C127, 
C49 and C167) that participate in formation of disulfide bridges are highlighted in 





Figure 1.3 Structure of IL-6 with the α-helices A, B, C and D identified 
Also shown on top right corner is the “up-up-down-down” topology of the tertiary 
structure of IL-6. A similar structure and topology are observed for other 
cytokines. (PDB: 1ALU) 
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Structural analyses by NMR and X-ray crystallography indicated that the 
cytokines can be classified into three groups based on the length of their helices 
(10-12) (Figure 1.4). 
 
1) Short-chain cytokines that have 8–10 residues e.g. IL-2 and IL-4 
2) Long-chain cytokines that have 10–20 residues e.g. IL-6 family cytokines, 
human growth hormone (hGH) and erythropoietin (EPO) 
3) Cytokines that have eight-α-helices forming a duplicated version of the 
‘four-α-helix bundle’ structure e.g. IL-5 and interferon (IFN)-γ 
 
The IL-6 family of cytokines, comprising IL-6, IL-11, leukemia inhibitory factor 
(LIF), OSM, ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1) and 
cardiotrophin like cytokine (CLC) fall under the category of long chain cytokines 
(13). With the exception of CNTF and CT-1, all IL-6 family cytokines are classical 
secretory proteins synthesized with N-terminal signal peptides (14). All these 
cytokines have 180 – 200 amino acids that collectively exhibit a low sequence 
homology (~20%). Together, these cytokines execute a broad range, but often 
overlapping biological activities mediated by the formation a multimeric receptor 
complex which includes a common receptor gp130. While IL-6 and IL-11 form the 
signaling complex by homodimerizing gp130s, all other IL-6 family cytokines 
heterodimerize gp130 with either leukemia inhibitory factor receptor (LIFR) or 





Figure 1.4 Crystal structures of IL-2, IL-6 and IFN-γ. 
Clearly, IL-2 and IL-6 display the signature four-α-helix bundle like structure. 
However, IL-2 is primarily comprised of short-chain α-helices while IL-6 is made 
up of long-chain α-helices. INF-γ on the other hand exists as a dimer comprised 
of two four-α-helix bundle like structures. (PDB IDs: IL-2 – 1M47; IL-6 – 1ALU; 





Figure 1.5 Receptor complexes of IL-6 family cytokines 
IL-6 type cytokines signal through different combinations of the signaling receptor 
subunits gp130, LIFR and OSMR with gp130 being used by all the family 
members. [Used with permission from Heinrich et al., (14)] 
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1.1.2. gp130 family of cytokine receptors 
 
On the basis of common structural features, cytokine receptors are grouped into 
six major categories: 
 
1. Class I cytokine receptors 
2. Class II cytokine receptors 
3. Tyrosine kinase receptors 
4. TNF receptors 
5. IL-1 receptors 
6. G-protein coupled receptors
 
The gp130 family of receptors, comprising gp130, LIFR, OSMR, IL-6Rα, IL-11Rα 
and CNTFRα fall under the class I cytokine receptors (Figure 1.6) (15). The class 
I receptors, also known as the hematopoietin receptors, constitute the largest 
group among the cytokine receptor family (7,16). These receptors have an N-
terminal extracellular and C-terminal intracellular orientation. Based on the ability 
to induce intracellular signaling, the gp130 family of receptors can be further sub-
divided into two categories (Figure 1.6) (13,17-29):  
 
1) Signal transducing receptors i.e. gp130, LIFR and OSMR and 




Figure 1.6 Domain composition of receptor subunits involved in IL-6 family 
cytokine signaling. 
The yellow lines in the n-terminal domain of cytokine binding domain (CBD) 
define the conserved disulfide bonds while the black line in the c-terminal domain 
defines the conserved WSXWS motif.  
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In most cases, the signal transducing receptors do not show appreciable affinity 
for cytokines. But, in the presence of specific α-receptors the cytokines can form 
high-affinity complexes with the signal transducing receptors that are capable of 
triggering intracellular signaling. IL-6 and IL-11 associate with their nonsignaling 
α-receptors IL-6Rα and IL-11Rα before binding to their signal transducing 
receptor gp130 while CNTFRα binds to the cytokines CNTF, CT-1, and CLC 
before they can form the signaling complex with gp130 and LIFR (19,28-30). This 
characteristic co-operative binding effect is used by the receptors as a means of 
imposing tissue specificity. For example, gp130 is expressed ubiquitously in the 
human body while IL-6Rα is expressed only on hepatocytes, lymphocytes, 
neutrophils and macrophages (31). Thus IL-6 can execute its function only on 
these cells. However, in situations when membrane bound IL-6Rα is shed from 
the cell surface by proteolytic cleavage, the circulating IL-6Rα binds to IL-6 
forming “IL-6 : IL-6Rα” complex which can now activate cells which are otherwise 
unresponsive to IL-6 (32-36). LIF and OSM are unique in this regard since these 
two cytokines do not require an α-receptor before they can bind to the signal 
transducing receptors LIFR or gp130. LIF can directly bind to LIFR and 
subsequently form a high affinity signal transducing complex with gp130 while 
OSM can directly bind to gp130 and then form a signal transducing complex with 
LIFR or OSMR.  
 
An additional characteristic feature of the gp130 family signal transducing 
receptors is that they are much longer than other cytokine receptors by the virtue 
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of three additional membrane-proximal fibronectin III like domains. The 
extracellular part of gp130 is composed of six contiguous β-sandwich domains; a 
single immunoglobulin (Ig) domain at the top, followed by one cytokine binding 
domain (CBD), and three fibronectin III-like domains leading to the cell 
membrane (See Figure 1.6). LIFR has an additional CBD over the Ig domain 
while OSMR has one extra β-sandwich domain at the N-terminus. The CBD 
essentially consists of two fibronectin type-III (FNIII) domains connected by a 
linker, and it represents the signature recognition module for helical cytokines. 
The upper, N-terminal domain contains four conserved cysteine residues that 
form interstrand disulfide bonds (37). The lower, C-terminal domain has a 
conserved WSXWS motif (38,39). Mutagenesis studies have shown an essential 
structural role for these amino acids in maintaining the tertiary structure of the 
protein, but they are not involved in cytokine interaction (40). The cytokine-
binding site for most CBDs is at the apex of the elbow region, consisting mainly 
of the interstrand loops connecting the β-strands from both N- and C-terminal 
domains (39,41). (Figure 1.7) The basic CBD is present in every class I cytokine 
receptor, and for some receptors such as the human growth hormone receptor 
(hGHR) (39) and the erythropoietin receptor (EPOR) (42), a single CBD is 
sufficient to mediate ligand binding and receptor homodimerization. However the 
gp130 family of receptors require additional domains like the Ig-like domain and 
membrane-proximal fibronectin domains to function and respond to the IL-6 






Figure 1.7 Crystal structure of LIF in complex with the cytokine binding domain 
(CBD) of gp130 
As it can be seen in the picture, LIF (shown in gray) binds gp130 (shown in 
rainbow colors with n-terminus in blue and c-terminus in red) in the apex of the 




1.1.3. Ligand-Receptor Interaction 
 
Cell signaling induced by secreted cytokines is a central biochemical mechanism 
for a diverse range of cellular functions and cell-cell communication. The initial 
step of binding to specific receptor(s) followed by subsequent activation of 
membrane-proximal and -distal intracellular signaling cascades lead to specific 
responses that control a diverse range of cellular functions. An issue of 
fundamental biological significance is the biochemical specificity of this ligand-
receptor interaction. This dictates both the identity and the kinetics of resulting 
signal transduction process and thus the associated biological responses. 
Important insights into the biochemical specificity of cytokine-receptor interaction 
have emerged from mutational and structural analysis of the cytokines and their 
receptors.  
 
The pioneering study of the interaction between human growth hormone (hGH) 
and the growth hormone receptor (GHR) (39) has provided important initial 
insights into the structural basis of ‘long chain’ cytokine-receptor interaction. The 
structural analysis revealed that a single molecule of hGH forms a homodimeric 
receptor complex by simultaneously binding two identical receptor subunits. Two 
discrete regions of the ligand, site I (comprising residues in helix D) and site II 
(comprising residues from helix A and C), each bind a receptor molecule via 
interaction with CHR. As a result of this simultaneous interaction with two sites 
on the ligand, the cytoplasmic domains of the receptor are brought into close 
proximity (44), triggering a GHR specific intracellular signaling cascade.  
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Structural and mutational analysis of IL-6 family cytokines revealed an important 
deviation from the classic ‘two-site’ model described above for hGH. IL-6 family 
cytokines instead have three distinct sites of interaction with their respective 
receptors (26,27,45-48). The first two sites, Site I and Site II are analogous in 
location to their hGH counterparts: site I is located at the C-terminus of helix D 
and site II is composed of residues in helices A and C. However, the defining 
feature of IL-6 family cytokines is the existence of a third binding site (Site III) 
which is located at the N-terminus of helix D. Matching the interaction epitopes of 
each cytokine with its respective receptors, reveals a combinatorial pattern of 
receptor engagement. Site I, if used, is always engaged by a non-signaling α-
receptor: IL-6Rα, IL-11Rα or CNTFRα (19,28-30,49). The glycoprotein gp130 
always interacts through binding site II and, depending on the cytokine the third 
binding site (site III) is used for recruitment of LIFR, OSMR or a second gp130 
receptor (18,21,23,26,27,50). 
 
This cytokine induced receptor oligomerization leads to the juxtaposition of the 
intracellular domains of the signal transducing receptors (Figure 1.8). Unlike 
receptors for many growth factors (e.g., insulin) that have intracellular domains 
possessing tyrosine kinase activity on the same polypeptide chain, the class I 
cytokine receptors have no intrinsic enzymatic activity. Rather, the intracellular 
domains of the class I cytokine receptors are constitutively associated with  





Figure 1.8 IL-6 signaling via the gp130/jak/STAT pathway 
IL-6 in presence of IL-6Rα leads to dimerization of two gp130 molecules. 
Associated Jaks become activated and phosphorylate the cytoplasmic part of 
gp130, thereby creating a docking site for STAT factors STAT1 and STAT3. 
Upon association, the Jaks phosphorylate STATs which then dissociate from the 
receptor and form homo- or hetro-dimers. These dimmers then translocate into 
the nucleus, where they regulate gene expression. APRF – acute-phase 
response factor; APRE – acute-phase response element; encircled Y – tyrosine; 
white P in black circle – phosphate. [Used with permission from Heinrich et al., 
(13)] 
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After the JAK kinases are activated by ligand-induced receptor oligomerization, 
they phosphorylate themselves and the tyrosine residues on intracellular 
domains of the receptors. The phosphorylated tyrosines in the receptors then 
serve as the docking sites for a second family of proteins, the signal transducer 
and activator of transcription (STAT) proteins. Binding of STATs to the 
intracellular domains of the receptors leads to their tyrosine phosphorylation and 
subsequent dissociation from the receptors. The phosphorylated STATs form 
dimers and translocate into the nucleus, where they bind to DNA recognition 
sequences and act as transcription factors (53-55) (Figure 1.8). Besides the 
major JAK-STAT signaling pathway, the class I cytokine receptors also use other 
signaling mechanisms such as the RAS-RAF-MAP kinase pathway (56) and PI3 
kinase (57,58).  
1.1.4. Mapping Binding Sites on the Cytokines 
 
The availability of high resolution structural data combined with functional 
analysis of receptor activation by mutagenesis studies lead to the definition of the 
structural features involved in receptor recognition by the IL-6 family of cytokines. 
These studies revealed that receptor interaction, involves a recognition ‘hot spot’ 
that is dominated by a small number of amino acid residues located close 
together in space. Structural and mutational analysis of LIF (41,48) and OSM (4) 
have shown that the interaction with gp130 via site II involves a small cluster of 





Figure 1.9 Comparison of site II residues on hLIF and hOSM 
Both molecules exhibit a remarkable conservation in the identity and structural 
orientation of the residues that make up the site II responsible for gp130 binding. 










This functional epitope is dominated by a conserved glycine (Gly) residue that, as 
a consequence of the absence of a side chain, forms a hydrophobic cavity in 
helix C. The neighboring asparagine (Asn) residue and two glutamine (Gln) 
residues from helix A further stabilize the interaction with gp130 (4,41) via 
formation of hydrogen bonds and polar interactions. The crystal structure of 
gp130 CBD (59) combined with mutagenesis data (60) provides a structural 
explanation for this interaction. The solvent-exposed hydrophobic residue 
(Phe169) and an adjacent tyrosine residue (Tyr196) on the CBD surface of 
gp130 are prominent determinants of this interaction. The exposed Phe169 
docks nicely into the hydrophobic cavity on hLIF/hOSM surface formed by the 
respective Gly125/Gly120 residues on helix C. In this configuration, the hydroxyl 
group of gp130 Tyr196 can form a hydrogen bond with the exposed amide group 
of adjacent asparagine (Asn129/Asn124) on helix C (Figure 1.10). Consistent 
with these observations, mutating Gly120 on hOSM to a bulky tyrosine residue 
severely disrupts its interaction with gp130 while substitution to alanine, a residue 
with relatively small non-polar side chain, has a mild effect (4). CNTF has a 
tyrosine residue on its helix C in the equivalent location of Gly on hOSM. This 
explains why CNTF interacts with gp130 at a much lower affinity than either hLIF 
or hOSM (4). The recruitment of an α-receptor, CNTFR, is hypothesized to 
compensate for this loss of affinity by inducing allosteric changes in CNTF, 
thereby introducing additional sites for both ligand-receptor and receptor-receptor 
interaction into the complex (61). Similar to above cytokines, Site II of IL-6 and 
IL-11 are also dominated by residues in helices A and C. For IL-6, Tyr31, Gly35 
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from helix A and Ser118, Val121 from helix C are the primary residues involved 
(62) while for IL-11, Leu45 from helix A and Arg135, Arg139 and Leu142 from 
helix C are essential for binding to gp130 (63) (Figure 1.11). Both these cytokines 











Figure 1.10 Complementarity between the interaction surfaces of hOSM and 
gp130 
The solvent accessible residues that make up the site II on hOSM (left) and the 
cognate binding site on gp130 (right) are displayed. Residues that complement 
each other in this binding are color coded accordingly [Used with permission from 



















Figure 1.11 Site II residues of IL-6 and IL-11 responsible for gp130 binding. 
While the structure of IL-6 is based on crystal structure solved (PDB: 1ALU), 
structure of IL-11 represents model prediction by Tacken et al., (63) (Used with 
permission from Tacken et al., (63)). Again, as in LIF and OSM, residues in 




Among IL-6 family cytokines, there are two sub-classes of cytokines. While both 
classes of cytokines interact with gp130 at site II, IL-6 and IL-11, interact with a 
second gp130 at their site III, while the second sub-class, comprising LIF, OSM, 
CNTF, CT-1 and CLC, interact with LIF-R at their site III. The site III of all LIFR 
interacting cytokines is dominated by two residues (4,13,47,48); a conserved 
solvent-exposed phenylalanine (F) and an adjacent lysine (K), commonly termed 
as the ‘FXXK’ motif (Table 1.1 and Figure 1.12). Structure of hLIF in complex 
with mLIFR revealed that the lysine side chain in the FXXK motif forms strong 
hydrogen bonds with Ser262 and Asn265 in the Ig domain of LIFR (64). In 
addition, a significant hydrophobic interaction is made by the π-stacking 
arrangement of the Phe156 of hLIF against the peptide bond of Gly276 in mLIFR. 
Together, these non-covalent interactions between LIF and LIFR lead to the 
formation of a tight complex with an equilibrium dissociation constant (KD) in the 
nano molar range. Parallel mutagenesis studies of IL-6 and IL-11, which interact 
with gp130 via site III (46,65) reveal a similar arrangement of a solvent-exposed 
hydrophobic residue tryptophan (W) and an adjacent acidic residue, aspartate 
(D) (46,62) (Figure 1.12). Based on these observations, it has been hypothesized 
that the hydrophobic core of all these cytokine binding sites is utilized to bind the 
receptor while the polar contacts surrounding the hydrophobic patch determine 
the specificity of the interaction. Interestingly, OSM which can bind LIFR at its 
site III can also uniquely bind to a separate receptor called OSMR. The same 
FXXK motif on OSM is shown to be essential for its interaction (4). This again 
implies that the difference in receptor specificity between LIF and OSM is a result 
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of structural differences between these ligands in the vicinity of the core FXXK 
motif (4). However, to date, residues on OSM that are uniquely responsible for 











Figure 1.12 Surface representations showing the site III interfaces of OSM, LIF 
CNTF and IL-6. 
The site III of OSM, LIF and CNTF which engages LIFR is defined by a 
conserved ‘FXXK’ motif. On the other hand, a tryptophan and an aspartate 
residue make up the site III for IL-6. These residues participate in engaging a 
second gp130 receptor onto IL-6. (PDB IDs: OSM – 1EVS; LIF – 1EMR; CNTF – 
















Table 1.1 Site III amino acid sequences of various IL-6 family cytokines. 
The FXXK motif is conserved among the cytokines that engage LIFR while a 
tryptophan replaces the phenylalanine in IL-6 and IL-11 which engage gp130 at 










By analogy with growth hormone, site I residues are defined as those residues 
that interact with their respective α-receptors. As described earlier, LIF and OSM 
do not require binding to an α-receptor before they can bind their signal 
transducing receptors LIFR and gp130. Thus, site I is not defined for these two 
cytokines. Based on the clues from hGH, site directed mutagenesis of residues 
at the C-terminal of the IL-6 family cytokines (IL-6 (66), IL-11(63,67), CNTF 
(68,69), CT-1 (30) and CLC (70)) yielded several mutants that lack bioactivity as 
well as the ability to bind to their α-receptors. While some residues directly 
participate in receptor binding, others are required for maintaining the structural 
integrity of the cytokine. In most of these cytokines, arginine (Arg) residue 
located at the end of their D helix was found to be essential for the interaction 
with the respective α-receptor. Structural analysis of IL-6 in complex with IL-6Rα 
revealed that this arginine (Arg179) forms polar contacts with Tyr230 and Glu277 
in the N-terminal half of the CBD of IL-6Rα (71). Gln175, Arg182 and Phe74 of 
IL-6 are also shown to be involved in this interaction by providing additional polar 











Figure 1.13 Site I residues of IL-6 that participate in IL-6Rα binding. 
Arg179 forms the core of this interaction while the surrounding residues Gln175, 
Phe74 and Arg182 stabilize this interaction by providing additional polar and 
hydrophobic contacts with the receptor. Helices A, B, C and D are indicated in 
black letters. Also, shown for reference is the tryptophan residue (green) at the 
top that makes up the site III which is essential for gp130 binding. (PDB: 1ALU) 
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Other mutations in this region which affect binding Ser177, Ala180, Leu178 and 
Leu181 are all buried and may be affecting activity by altering the local 
conformation of IL-6 (62). Structural analysis of this region also revealed that 
there is a high density of ordered water molecules which may play a role in 
binding the receptor by adding entropy to the system as they are displaced 
(Figure 1.14) (62). Similar to IL-6, IL-11 and CNTF also utilize an arginine residue 
(Arg190 for IL-11 and Arg177 for CNTF) on the c-terminus of their D helix as the 
core of site I while the other residues nearby stabilize the interaction with polar 





Figure 1.14 Water molecules (red spheres) in the region between the helix D 
and the A-B loop of IL-6. 













Figure 1.15 Site I residues of CNTF and IL-11 that play a key role in binding 
CNTFRα and IL-11Rα respectively. 
Again, the arginine residues on helix D (Arg177 on CNTF and Arg190 on IL-11) 
form the core of this interaction while the residues around stabilize the interaction 
by providing additional contacts. (PDB ID of CNTF: 1CNT). Model structure of IL-




1.1.5. Stoichiometry of Signaling Complexes 
 
Based on the structures solved for IL-6 family cytokines in complex with their 
receptors and mutational analysis conducted on the receptors by deleting 
domains, it has been identified that 1) the α-receptors always utilize the residues 
in their CBD to bind site I 2) gp130 always utilizes residues in its CBD to bind site 
II and 3) receptors that bind at site III, always utilize residues in their IgD (Table 





Table 1.2 Composition of IL-6 family cytokine receptor complexes 
 
 
Shown in the table are the receptors and their domains that participate in binding 
to each of the IL-6 family cytokine. While IL-6 and IL-11 bind gp130 receptor at 
their site III, all other IL-6 family cytokines engage LIFR at their site III. However, 
the receptors always use a CBD to engage site I (except for LIF and OSM), a 
CBD to engage site II and an Ig domain to engage site III. 
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However, there is a striking contrast between the IL-6/IL-11 systems and the 
LIF/CNTF/OSM/CT-1/CLC systems of receptor complex formation. IL-6 first 
engages IL-6Rα CBD through site I to form a binary complex, followed by a low-
affinity recruitment of the gp130 CBD through site II to form a non-signaling 
ternary complex. The final step is a high affinity dimerization of two gp130/IL-6/Il-
6Rα heterotrimers via site III where the IgD of gp130 (the CBD of which is 
already bound to site II of partner IL-6) binds (71). When alone, gp130 IgD does 
not exhibit any affinity towards IL-6 site III. The dimerization of two trimeric 
complexes introduces additional contacts between the cytokine and the 
receptors, stabilizing the weak interaction between IL-6 and gp130 IgD at site III 
(Figure 1.16). Thus, the formation of a hexameric complex is essential for IL-6 to 
induce homodimerization of gp130 which can then trigger the activation 
intracellular signaling cascade. Similar to IL-6 system, CNTF first engages 
CNTFRα CBD at its site I. And, as in IL-6 system, this pre-complexation with 
CNTFRα is required for CNTF to engage gp130 CBD at its site II. However, in 
contrast to the IL-6 system, IgD of gp130 that is bound to site II does not 
participate in site III interaction. Instead, IgD from a separate receptor (LIFR) 
occupies this position. Binding studies revealed that pre-complexation of either 
CNTFRα or the gp130 is not required for CNTF binding to LIFR (61). Similar 
observation is made in LIF system where pre-complexation with gp130 is not 





Figure 1.16 Schematic diagram of the hexameric receptor complex assembly for 
IL-6 
The representation for Ig domains and CBDs are as described in figure 1.6. The 
four-α-helical IL-6 is represented in red while IL-6Rα and gp130 are represented 
in green respectively. Sites I, II and III are represented in yellow circles. IL-6 first 
binds IL-6Ra via its site I and then recruits a gp130 at its site II. However, unlike 
LIF and CNTF, IL-6 does not engage LIFR at its site III. Instead, two IL-6 
molecules form two separate IL-6-IL-6Rα-gp130 complexes engage the Ig 
domain of gp130 from opposite complex to form a hexameric complex. This kind 
of complex formation stabilizes the weak interaction between gp130 IgD and site 





Figure 1.17 Three-dimensional model structures for IL-6 family cytokines in 
complex with their receptors. [ Used with permission from Skiniotis et al., (61)] 
These structures represent the three classes of receptor complex engagement 
seen in IL-6 family cytokines. 1) Hexameric complex (IL-6, IL-11), 2) quaternary 
complex (CNTF, CT-1, CLC) and 3) trimeric complex (LIF, OSM). Unlike LIF and 
CNTF which exhibit a strong interaction with LIFR through their site III, IL-6 
requires the formation of a hexameric complex to stabilize its weak interaction 
with gp130 at its site III. And, unlike other IL-6 family cytokines, LIF and OSM 
exhibit a direct affinity towards their signal transducing receptors (LIFR or gp130) 
and do not require an α-receptor for forming the signaling complex.  
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This implies that, unlike IL-6, CNTF and other cytokines that heterodimerize 
LIFR/gp130 do not require the hexamer formation to trigger intracellular signaling 
cascade (Figure 1.17). The high affinity interaction of LIFR with these cytokines 
via FXXK motif negates the requirement of affinity enhancement through the 
hexamer formation.  
 
1.2. Biological activities of OSM & other IL-6 family cytokines 
 
IL-6 family cytokines, including OSM, act on a wide variety of cells and elicit 
diverse overlapping biological responses such as inflammation, neuroprotection, 
haematopoiesis and development. The functional redundancy of the IL-6 family 
cytokines can be explained by their shared receptor subunits. However, it has 
also been recognized that each of these cytokines exhibit unique activities that 
are not shared by other family members. These unique activities are conferred by 
their specific receptors and their restricted expression. 
1.2.1. Inflammation 
 
Inflammation refers to a complex set of mechanisms by which tissues respond to 
injury and infection. The initial signs of swelling, pain and heat are characteristics 
of the initial phase of inflammation, termed as acute inflammatory response 
(72,73). This is characterized by increased blood flow, increase in permeability of 
the surrounding capillaries and infiltration of white blood cells, predominantly 
neutrophils (74-78). In case of severe damage, this reaction is followed by the 
chronic inflammatory response where the affected tissue is infiltrated by 
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lymphocytes, macrophages, and mast cells (79). Substantial tissue remodeling 
can occur during this phase which may lead to complete restoration of normal 
tissue architecture or a scar formation (80). This complex chain of events is 
regulated by an array of mediators, which includes cytokines, the extracellular 
matrix, and adhesion molecules (79,81-83). 
 
Activated T cells and monocytes at the site of injury/infection secrete Oncostatin 
M (84,85) which in turn stimulates endothelial cells to secrete IL-6 in the blood 
stream (86). IL-6 then stimulates the liver to secrete acute phase proteins (APPs) 
into circulation (87). APPs are essential for controlling body homeostasis and 
regulate the inflammatory response. While other IL-6 family cytokines like LIF, 
CNTF and IL-11 also stimulate the release of APPs from the liver (87-96), IL-6 
was found to be the primary inducer of APPs in vivo (87). In addition to the APPs, 
OSM and IL-6 are shown to modulate the expression of other cytokines and 
chemokines involved in inflammation e.g., IL-1, IL-8, granulocyte macrophage-
colony stimulating factor (GM-CSF), growth related oncogenes α and β (97). 
Also, OSM induces prolonged expression of P-selectin (98) and E-selectin (97) in 
endothelial cells which modulate leukocyte adhesion and extravasation. This is 
an important phenomenon involved in wound healing.  
 
During the repair process, remodeling of extracellular matrix plays an important 
role in healing the damaged tissue. Matrix metalloproteinases (MMPs) are 
involved in extracellular matrix breakdown while tissue inhibitors of 
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metalloproteinases (TIMPs) inhibit the action of MMPs (99-104). OSM plays a 
crucial role in this process by modulating the expression of TIMP-1 (105) and 
MMP-1, MMP-3 and MMP-9 in fibroblasts (106) at the wound site. 
 
Besides acute phase reactions, IL-6 family cytokines are also associated with 
several acute and chronic inflammatory diseases e.g., rheumatoid arthritis, acute 
pancreatitis, and Alzheimer’s disease. In patients suffering from rheumatoid 
arthritis, elevated levels of IL-6, IL-11, LIF and OSM have been found in the 
synovial fluids and the serum (107-118) and the levels of these cytokines were 
shown to correlate with disease severity. Research has shown that these 
cytokines induce bone remodeling (119-121), stimulate cartilage degradation 
(122-124) and induce osteoblast proliferation (125,126). Injection of anti-IL-6 
receptor monoclonal antibody and LIF antagonists were shown to ameliorate 
inflammatory reactions in these inflammatory models (127).  
1.2.2. Neuroprotection 
 
IL-6 family cytokines LIF, CNTF, OSM and CT-1 all of which signal through 
heterodimerization of gp130 with LIFR exhibit a wide range of roles in both the 
developing and mature nervous system. They play a vital role in modulating the 
differentiation of neuronal cells and promote their survival under stress 
conditions. While most of these cytokines are expressed in various parts across 
the body, CNTF is found exclusively in the nervous system.  
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Initial studies using cytokine knockout models revealed no abnormalities in 
development (128,129) suggesting that these cytokines are not essential for 
neuronal development. However, CNTFRα and LIFR knockout mice died within 
24 h of birth and had a marked reduction in numbers of spinal motor neurons 
(128,130,131) indicating that these cytokines in fact play an important role in 
neuronal survival and the overlapping signals executed by IL-6 family cytokines 
compensate for the loss of others. Although neurons and astrocytes are known to 
express LIF, CNTF, and OSM, glial cells are considered to be the major 
producers of these cytokines (20,132) and this expression is up regulated upon 
injury or stress by an as yet unknown mechanism. And, in vivo the neurons and 
astrocytes are closely associated with the glial cells thus exposing them to high 
concentrations of glial-derived neurotrophic factors and cytokines upon ischemic 
or excitotoxic injuries (133,134).  
 
Excitotoxic pathways initiated after excessive glutamate release have been 
implicated in traumatic spinal cord injury, stroke and some chronic age-related 
neurodegenerative diseases like Alzheimer’s disease (135). OSM was shown to 
significantly attenuate the neuronal cell death induced by a similar excitotoxic 
injury triggered by N-methyl-D-aspartate (NMDA), an analogue of glutamate, 
both in vitro and in vivo (136). Similar observations were made for CNTF. 
Treatment with exogenous CNTF was shown to protect the neurons after a CNS 
injury induced by both excitotoxic stimulation and by degenerative diseases like 
multiple sclerosis (MS) and Huntington’ disease (137-142). Delivery of LIF, CNTF 
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and OSM have been demonstrated to be neuroprotective in a number of other in 
vitro and in vivo models also (136,143-145). In the eye, studies by La Vail et al., 
(146-148) have shown that multiple neurotrophic factors including CNTF rescue 
photoreceptors from damaging effects of constant light and retinal degenerations 
induced by inherited genetic mutations. Recent work in our lab by Ueki et al., 
(149) has shown that LIF, another IL-6 family member also protects the 
photoreceptors from oxidative stress induced by severe bright light. Later, knock 
out studies by Joly et al., (150) have shown that endogenous LIF extends the life 
span of retinal photoreceptors in a mouse with degenerating retina induced by 
genetic mutations. In addition to these, studies by Rattner et al., (134) have 
shown that the retina responds to severe light stress by up regulating the 
expression OSMR, suggesting a possible role of neuroprotection by OSM. 
Together, all these results clearly suggest that IL-6 family cytokines play an 
important role in protecting the neuronal cells from oxidative stress induced by 
injury or inherited genetic mutations. Separate studies have shown that 
preconditioning the eyes with bright cyclic light or with hypoxia also help the 
photoreceptors survive subsequent doses of severe oxidative stress (151-155). 





Hematopoiesis can be broadly defined as the regulation of the concentrations of 
cellular components in blood. In a healthy adult, approximately 1011 – 1012 new 
blood cells are produced daily in order to maintain the steady state levels (156). 
All of these cellular blood components are derived from hematopoietic stem cells 
(HSCs) which reside mainly in the bone marrow. These stem cells can proliferate 
and differentiate leading to the production of one or more specific types of blood 
cells. A number of factors control this process of proliferation and differentiation 
with great precision and regulate the production of blood cells. 
 
While erythropoietin (Epo) and granulocyte-macrophage colony stimulating factor 
(GM-CSF) are the primary mediators of this regulation, IL-6 family cytokines also 
play an important role. mRNA levels for IL-6, IL-11, OSM and LIF are found to be 
abundant in hematopoietic tissues such as bone marrow, thymus and spleen 
(13,157). These cytokines, in concert with IL-3 are shown to regulate the 
proliferation of pluripotent hematopoietic progenitor cells by controlling their entry 
and exit from the cell cycle (158-160). Also, intravenous administration of LIF, 
OSM, IL-6 and IL-11 were all shown to result in dramatic increase in 
megakaryocyte and platelet numbers in the blood (161-166). In addition, IL-6 
family members are also shown to inhibit the differentiation of macrophages and 
several myeloid leukemic cells indicating that these cytokines play an important 
role in final maturation of the hematopoietic cells (167-169).  
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1.2.4. Other Functions of Oncostatin M 
 
 
1.2.4.1 Growth Modulation of Tumor Cells: 
 
Oncostatin M was originally identified by virtue of its ability to suppress tumor 
cells. It was originally recognized in 1986 by its ability to inhibit the proliferation of 
A375 melanoma cells (1). Later, it was shown to inhibit the growth of several 
other types of tumor cells including lung cancer cells, breast cancer cells, glioma 
cells and solid tissue tumor cells (170-172). LIF, another IL-6 family member 
closely related to OSM, was not able to display a similar ability in suppressing 
tumor cells suggesting that OSM executes these functions by recruiting its 
unique receptor OSMR. In agreement with these observations, more recent 
studies by Lacreusette et al., (173) have shown that melanoma cell progression 
towards an OSM resistant metastatic state is accompanied by silencing of the 
OSMR gene. Thus, in addition to designing novel agonists of OSM, preventing 
the alteration of promoter region of OSMR can be a potential avenue to suppress 
the proliferation of tumor cells in vivo. Besides tumor cells, OSM also inhibits the 
proliferation of normal mammary and breast epithelial cells (174). In contrast, 
OSM stimulates the growth of AIDS related Kaposi’s sarcoma cells (175-177) 
and the normal dermal fibroblasts via mitogen-activated protein kinase (MAPK)-
dependent pathway (178).  
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1.2.4.2 Regulation of Cholesterol Levels: 
 
Increased low density lipoprotein-cholesterol (LDL-c) levels in plasma is a widely 
recognized risk factor for atherosclerosis and an important underlying cause for a 
number of cardiovascular diseases (179-183). The LDL receptor (LDLR) plays a 
pivotal role in the control of plasma cholesterol levels since more than 70% of the 
LDL-c in circulation is removed by LDLR-mediated endocytosis (184,185). 
Therefore, the regulation of liver LDLR expression has been considered a key 
mechanism by which therapeutic agents could interfere with the development of 
atherosclerosis. 
 
Over the past three decades, statins (e.g., Rosuvastatin (Crestor®), Atorvastatin 
(Lipitor®), Lovastatin (Mevacor®)) have been extensively studied and applied in 
the clinical setting to serve as cholesterol depleting agents (179,180,186). They 
lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which is 
the rate-limiting enzyme involved in cholesterol synthesis (184). Inhibition of this 
enzyme in the liver not only decreases cholesterol synthesis, but also increases 
synthesis of LDL receptors, leading to an increase in clearance of LDL-c from the 
bloodstream. In addition to these, LDLR expression levels were also shown to be 
regulated by several growth factors and cytokines (187-202). However, among 
these, OSM was shown to have the most pronounced effect in increasing the 
levels of LDLR on liver. When administered intraperitoneally, OSM was shown to 
induce rapid upregulation of LDLR expression in liver and this upregulation was 
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sustained for 24 hrs (203). In addition, when tested in combination with the 
commercially available statins, OSM was found to show an additive effect (204). 
Further investigation showed that OSM regulates the LDLR expression through a 
separate statin independent mechanism (205). Clinical studies are under way to 
use OSM as a potential therapeutic agent to regulate cholesterol levels either 
independently or in combination with the currently available statins. 
 
1.3. Controlled Drug Delivery 
 
Healthcare providers have traditionally been using pills, ointments and injections 
for delivering drugs into the body.  While these modes proved effective in treating 
a number of disease states, they are inefficient for delivering sensitive drugs that 
lead to serious toxicity when delivered in large doses and those that have short 
half-lives. The primary aim of any drug delivery mode is to maintain the drug 
concentration at therapeutic levels for desired duration. Traditionally, this aim has 
been achieved by repeated dosages that cyclically alter the in vivo concentration 
of the drug and thus maintain its levels in therapeutic range for longer durations. 
The drug concentration in blood increases after each administration and as the 
drug is consumed by the body, the drug concentration decreases until the next 
dosage is administered (Figure 1.18). However, repeated dosages often result in 
drug delivered outside the therapeutic region, including drug concentrations 
beyond the toxic level that can lead to serious side effects (206-209).  Therefore, 




Figure 1.18 Changes in systemic levels of drug concentrations with traditional 
methods of repeated cyclic administration 
Immediately after administration, drug concentrations shoot up beyond the 
therapeutic ranges possibly leading to toxicity and as the drug is consumed by 




consistently maintain the drug concentration in the desired therapeutic region 
(210). These interests are the motivation behind the concept of “Controlled Drug 
Delivery”. Controlled drug delivery can be broadly defined as a judicious release 
of drug or any other active agent in a predesigned fashion (211-213). Release 
rates can be constant over long periods, cyclic or triggered as needed by the 
environment or other external agents (Figure 1.19). In any case, the purpose is to 
achieve more effective therapies while eliminating the potential for both under 
and over dosing. Additional advantages of controlled drug delivery include the 
need for fewer number of drug administrations, more effective usage of the drug 
and increased patient compliance. For these advantages to be exploited, 
choosing a proper drug delivery system is essential. An ideal drug delivery 
system should be inert, biocompatible, mechanically strong, capable of achieving 














Figure 1.19 Changes in systemic levels of drug concentrations with ideal modes 
of controlled drug delivery 
Shown in solid line is the delivery mode where encapsulated drug is released at 
a constant rate over long periods of time. Shown in dashed line is the delivery 
mode where the drug is delivered cyclically in a predetermined fashion. In either 
case, the drug concentrations stay in therapeutic range for long durations 
minimizing the effects of under or over doses. Also, the need for fewer 
administrations to obtain desired therapeutic effect makes these methods more 






Hydrogels are a versatile class of materials that meet most of the criteria required 
by a controlled release system. They can be generally defined as insoluble, yet 
water swellable polymer networks. Hydrogels may absorb from 10% to up to 100 
times their dry weight in water (214). Hydrogels may be chemically stable or they 
may degrade and eventually dissolve in aqueous solutions. Since the pioneering 
work of Wichterle in 1960s (215-217) hydrogels have become materials of great 
interest to biomaterials scientists. Later, Yannas and co-workers incorporated 
natural polymers such as collagen and shark cartilage into hydrogels for use as 
artificial burn dressings (218,219). Hydrogels based on both natural and synthetic 
polymers have since then been great candidates for encapsulating and delivering 
various proteins, cells and therapeutic agents (Table 1.3) (220-222). More 
recently, these hydrogels have become especially attractive to the field of tissue 
engineering as matrices for repairing and regenerating a wide variety of tissues 










Table 1.3 Examples of natural and synthetic polymers commonly used in 




Natural Polymers Alginic acid, Chitosan,  





Poly(ethylene glycol) (PEG) 
Poly(lactic acid) (PLA) 
Poly(glycolic acid) (PGA) 
Poly(lactic acid-co-glycolic acid) (PLGA) 
Poly(2-hydroxy ethyl methacrylate) (PHEMA) 
Poly(N-vinyl pyrrolidone) (PNVP) 












1.3.2. Types of Hydrogels 
 
Hydrogels can be broadly divided into two major classes; 
1. Physical (reversible) 
2. Chemical (permanent) 
‘Reversible’ or ‘physical’ hydrogels are formed when the polymer networks are 
held together by molecular entanglements and/or physical forces that include 
hydrogen bonding, ionic, electrostatic or hydrophobic forces (242,243). 
‘Permanent’ or ‘chemical’ hydrogels are formed when the polymers/macromers 
are held together by covalent-crosslinking (244-246) (Figure 1.20). Based on the 
chemical composition, these hydrogels can be either degradable or non-















Figure 1.20 Schematic of methods for forming physical and chemical hydrogels 
Examples of physical hydrogel include alginic acid in complex with Calcium or 
polylysine. Examples of chemical hydrogel include photopolymerization of 
diacrylated poly(ethylene glycol) (PEG) using photoinitiators. 
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In addition, the water inside the hydrogel can exists in two forms (214): 
1. Primary bound water (water that hydrates the most polar hydrophilic 
groups) 
2. Secondary bound water (water interacting with the hydrophobic domains 
that are exposed by swelling of the gel) 
Combined, these two forms are often called ‘total bound water’. After the polar 
and hydrophilic sites have interacted with the water, additional water is imbibed 
due to the osmotic driving force of the network chains towards infinite dilution. 
This induces swelling which is opposed by the covalent or physical crosslinks, 
leading to an elastic network retraction force (250). Thus, the hydrogel will reach 
an equilibrium swelling level at the point where these two opposing forces are 
equal. The extent of this swelling level is determined mainly by the nature of the 
hydrophilic chains and the crosslinking density of the network (250,251). Release 
of the macromolecular drugs from these hydrogels is primarily controlled by the 
pore size and the amount of water available for the drug to freely hydrate and 
diffuse through (244,246,251-253). However, additional parameters like the 
polymer chemistry, and its strength of interaction with the encapsulated drug may 
also play an important role in determining the release rates of the drug. In 
designing a hydrogel matrix for a controlled release application, it is thus 
essential to match the polymer composition and the crosslink density of the 




1.3.3. Polymers in Controlled Drug Delivery 
 
A range of polymeric materials are now being employed to control the release of 
drugs and other active agents, primarily because of their processability and the 
ability of researchers to readily control their chemical and physical properties via 
molecular synthesis. Shown in table 1.4 are some of the polymers that are 
currently being used for synthesizing hydrogels along with their desirable 
properties. 
 
Early generation of polymers/macromers that made up the hydrogels were 
usually homopolymers (eg. PEG, PMMA) which displayed specific properties. 
However, the desire to fabricate materials that possess multiple properties have 
lead chemists to create co-polymers (eg. PLGA (254,255)) and block co-
polymers (eg. PLA-PEG-PLA (244)) that became more attractive for drug delivery 
applications. For example, PEG is one of the most biocompatible polymers 
because of its high hydrophilic nature. The tight hydrogen bond formation 
between PEG and the water molecules around prevent it from adsorbing any 
protein or biological matter onto its surface. This property has made PEG very 
attractive for synthesizing hydrogels and as a coating on bio-implants to prevent 
rejection from the immune system (256). Many research groups have also 
investigated the attachment of PEG chains onto therapeutic proteins since PEG 
chains at the surface allow proteins to stay in circulation for longer durations 
(257-264).  
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Table 1.4 Chemical structure and desirable properties of some of the common 
polymers used in synthesis of hydrogels. 
PEG – poly(ethylene glycol); PGA – poly(glycolic acid); PLA – poly(lactic acid); 
PMMA – poly(methyl methacrylate); PVA – poly(vinyl acetate); PAA – poly(acrylic 
acid); PNIPAAM – poly(N-isopropyl acrylamide).  
 
 
Polymer Structure Desirable Properties 
PEG 
 


























While the non-degradable PEG hydrogels are very inert and trigger minimal to no 
immune response, its applicability has been limited since it requires surgical 
procedures to remove the gel once the drug is delivered. Incorporating PLA on 
one or both sides of the PEG chain allows the formation of block co-polymers 
PLA-PEG or PLA-PEG-PLA. These block co-polymers are extremely attractive 
for applications in drug delivery (244,245) since they posses both of the highly 
desirable properties 1) the hydrophilic surface which prevents protein adsorption 
and immune rejection and 2) the ability to degrade and dissolve in water.  
 
In addition to these, some polymer materials have allowed the development of a 
novel concept of ‘responsive drug delivery’ where the drug is released from the 
hydrogel in a pulsatile manner only when required by the body (283,284). Much 
work in this area has the eventual goal of delivering insulin to diabetic patients. 
Insulin requirements fluctuate throughout the day as patient food intake and 
activity change blood glucose levels. Current insulin formulations require 
repeated injections daily and careful control of glucose intake. Responsive drug 
delivery hopes to revolutionize insulin therapy with the design of systems that 
release insulin in response to increased blood glucose levels. In general, 
responsive drug delivery systems have two components: a sensor that detects 
the environmental parameter that stimulates drug release and a delivery device 
that releases drug. For diabetes treatment, responsive drug delivery systems 
have been proposed that use the enzyme glucose oxidase as the sensor (283). 
When blood sugar levels rise, glucose oxidase converts glucose to gluconic acid 
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resulting in lowered pH. This pH decrease is then used as the signal for insulin 
release. Release is achieved by pH-sensitive polymers that either swell or 
degrade in acidic environments (275). 
 
And finally, depending on the composition and the method of polymerization, 
hydrogels can be fabricated into many different physical forms that suit a variety 
of applications. These include (a) soft molded forms (soft contact lens), (b) 
pressed powder matrices (pills or capsules for oral intake), (c) microparticles 
(injections, ointments and wound dressings), (d) coatings (on implants and 
catheters), (e) membranes or sheets (reservoir in a transdermal drug delivery 
patches), (f) encapsulated solids (osmotic pumps), and (g) liquids (that form gels 
upon exposure to changes in temperature or pH).  
 
1.3.4. Mechanisms of Drug Delivery 
 
There are two primary mechanisms by which active agents can be released from 
a delivery system: 
1. Diffusion 
2. Degradation 
One or both of these mechanisms may occur in a given release system. In a 
diffusion-controlled release system, the diffusion of drug molecule within an 
aqueous environment is inhibited by the insoluble polymer matrix through which 
drug molecules must travel to exit the device (285). Polymer chains that form the 
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cross-linked hydrogel act as diffusion barriers. The swelling of hydrogel in water 
which creates void space for the polymer to imbibe more water in decreases 
these diffusion barriers (214,250). Polymers used for diffusion controlled release 
can be fabricated as either matrices (220-222,248,286) in which the drug is 
uniformly distributed or as membrane devices that protect a drug reservoir from 
releasing spontaneously (287-290). While in matrix systems, the drug diffuses 
through the void spaces between polymer chains out into the environment, 
diffusion out of reservoir system is determined by the osmotic potential gradients 
and the drug is transported out of the reservoir, driven by diffusion and 
convection through the orifices. Shown in figure 1.21 is a comparison of the 
diffusion mechanisms between the matrix and reservoir systems. Diffusion rates 
in a matrix system decrease with the release of drug owing to the gradual 
decrease in concentration gradient of the drug. However, for reservoir systems 
the delivery rates can remain fairly constant as since drug concentration inside 












Figure 1.21 Mechanisms of controlled drug delivery from A) matrix and B) 
reservoir devices 
In matrix devices, drug molecule diffusion is limited by the insoluble polymer 
matrix and the drugs must travel through the tortuous pathways to exit the 
device. However, in reservoir devices, the drug is trapped in a semi-permeable 
polymer membrane. High osmotic gradients drive water to diffuse in to the 
reservoir generating a pressurized chamber inside. This pressure is relieved as 
the aqueous solution along with the drug flows out of the orifices. The rate of this 
flow is determined by the size of orifices and the thickness and permeability of 
the polymer membrane to water.  
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While the hydrogel systems that are primarily diffusion controlled showed 
excellent promise for controlled delivery of drugs a great deal of attention and 
research effort is currently being focused on degradable polymers. These 
potential drug carriers degrade into biologically acceptable compounds, often 
through the process of hydrolysis, subsequently releasing the incorporated 
medications for uptake by living cells. This process eliminates the need to 
remove the delivery system after release of the active agent is completed.  
 
It is important to note that the term ‘degradation’ specifically refers to bond 
cleavage, whereas ‘erosion’ refers to depletion of material. Degradation is a 
chemical process that leads to size reduction of the polymer chains, while 
erosion is mass loss of polymer matrix by dissolution and diffusion processes.  
 
Two mechanisms of polymer erosion can be identified (Figure 1.22):  
1. Surface erosion 
2. Bulk erosion 
Surface erosion occurs when the rate of degradation exceeds the rate of water 
permeation, while bulk erosion occurs when water molecules are able to 
permeate into the bulk of the polymer matrix at a quicker rate than degradation of 
individual bonds. Homogenous (bulk) erosion where the polymer degrades 
homogeneously throughout the matrix is a common polymer degradation 





Figure 1.22 Mechanisms of drug delivery from a surface eroding vs. bulk eroding 
device. 
In surface eroding devices, polymer chains degrade at a faster rate than water 
permeation into the device. However, in bulk eroding devices, water molecules 
are able to permeate into the bulk of the polymer matrix at a quicker rate than 
degradation of individual bonds. 
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The hydrolysis of bulk degrading polymers usually proceeds by first losing 
molecular weight (i.e. larger chains breaking up into smaller units), followed by a 
loss of mass in the second stage (i.e. depletion of material from the hydrogel). 
The bulk degrading polymers commonly used are poly(esters), such as 
copolymers of PLA and PGA (254,291). However, bulk degradation causes 
difficulties in the control of drug release, because the release rate may change as 
the polymer degrades. As the polymer begins to lose mass, the release rate 
accelerates because it is determined by a combination of diffusion and 
simultaneous polymer erosion.   
 
In surface eroding systems, the erosion rate depends on the geometry and the 
surface area of the device rather than the volume of the polymer matrix 
(249,292,293). Here, the actual erosion process is the rate-limiting step and that 
the drug release rates depend on the erosion rate of the polymer. However, the 
surface area decreases as the implant is eroded, with a corresponding decrease 
in the release rates of drug. Thus, a geometry that does not change its surface 
area significantly as a function of time helps in attaining more uniform and zero-





Following introduction, chapter 2 outlines the details of materials and 
experimental procedures used in this research. In chapter 3, section 3.1, we 
characterize the role of IL-6 family cytokines in endogenous neuroprotection of 
retinal photoreceptors. Using quantitative PCR techniques, we provide evidence 
that in the retina, IL-6 family cytokines LIF, OSM, CT-1 and CLC are strongly 
upregulated in response to preconditioning with bright cyclic light leading to 
robust activation of STAT3 in a time-dependent manner. Further, we found that 
blocking LIFR activation during preconditioning using a LIFR antagonist (LIF05) 
(48,294) attenuated the induced STAT3 activation and also resulted in reduced 
preconditioning-induced protection of the retinal photoreceptors. Together, these 
data demonstrate that LIFR and its ligands play an essential role in endogenous 
neuroprotective mechanisms triggered by preconditioning-induced stress. 
 
In section 3.2, we present our results on the structural characterization of one of 
the IL-6 family cytokines, human oncostatin M (hOSM). It has previously been 
reported that unlike other IL-6 family cytokines, hOSM signals via two different 
receptor complexes (23,50), LIFR:gp130 (type I and OSMR:gp130 (type II). Also, 
unlike other LIFR binding cytokines in this family, OSM displays a weak affinity 
towards LIFR (5,21,50). Based on our structural analysis, we hypothesized that a 
unique loop structure between the B and C helices of OSM is playing a role in 
OSM’s unique ability to bind OSMR. However, functional evaluation of wild type 
OSM in comparison with mutant OSMs with truncated BC loops revealed that the 
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BC loop is not responsible for OSM’s unique ability to bind OSMR, but instead 
acts as a modulator for OSM’s affinity towards its receptors. Kinetic and 
equilibrium binding analysis of the ligand receptor interactions showed that the 
BC loop on OSM presents a steric hindrance for OSM’s strong interaction with 
both LIFR and OSMR. Removal of the loop resulted in creation of novel 
cytokines that exhibit improved affinity towards LIFR and OSMR, leading to 
improved ability in activating LIFR:gp130 and OSMR:gp130 receptor complexes 
on the cell surface. In section 3.3, we have tested the applicability of 
poly(ethylene glycol) (PEG) based hydrogels for delivering these cytokines in a 
controlled manner for therapeutic applications. With in vitro and in vivo 
experiments in mice, we show that the macromer content in the hydrogels can be 
varied to effectively manipulate the physical properties and thus the release rates 
of the encapsulated drug from these hydrogels. Using PEG 5000 Da macromers, 
we have shown that one can obtain a sustained release of hOSM for a period of 
12 days. And, for transscleral delivery of hOSM to retina, a release rate of at 
least 0.5 μg/day from the hydrogel is required to cross the scleral barriers and 
reach the retina to induce STAT3 activation. Finally, in chapter 4, we present our 
conclusions and recommendations. 
 64
2. MATERIALS AND METHODS 
 
2.1. Mutation of human Oncostatin M 
 
A cDNA clone for hOSM was obtained from Invitrogen (Cat # 4548943; 
Invitrogen, Carlsbad, CA). The gene encoding mature OSM is amplified using 
PCR (See Table 2.1 for primers). The gene is then cloned into a pGEX-2T vector 
(Catalog # 27-4801-01, GE Healthcare, Uppsala, Sweden) for protein expression 
as a GST fusion protein with a thrombin cleavage site between the GST tag and 
the protein. During the course of purification we observed that the native human 
OSM contained a cryptic thrombin cleavage site ‘AGR’ between its C and D 
helices (Figure 2.1). As expected, when this fusion protein was subjected to 
thrombin cleavage on a glutathione sepharose 4B column, it resulted in the 
formation of two new fragments of sizes ~17 kDa and ~6 kDa in addition to the 
native OSM which is ~23 kDa (Figure 2.2, lane 1). To facilitate recombinant 
protein purification and to increase protein stability in vivo, we induced mutations 
at DNA level using Quickchange® site directed mutagenesis kit (Stratagene, La 
Jolla, CA) to replace ‘AGR’ with ‘AGA’. This modification resulted in OSM that 
was resistant to thrombin cleavage (Figure 2.2, lane 2). The ‘AGA’ modification 
did not alter OSM’s functional activity on Müller cells (Figure 2.3). Treating 
human Müller cells with GST fused wild type hOSM (GST-hOSM (WT)) or the 
OSM modified with AGA (GST-hSOM (modified) resulted in similar levels of 
STAT3 activation in a dose dependent manner. This was expected since the 
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modification is located in a flexible loop region, away from the receptor binding 
sites. We will refer to this ‘AGA’ modified human OSM as the wild-type* OSM 
(OSM-WT*). Recombinant proteins with modifications in the BC loop (OSM-M1 
and OSM-M2) were made using the ‘AGA’ modified human OSM as the starting 
template. Therefore all recombinant OSM proteins we expressed lack the 
thrombin cleavage site. Mutations and/or deletions of codons in the BC loop 
region were performed using Quickchange® mutagenesis kit (Stratagene, La 






Figure 2.1 Amino acid sequence of human OSM. 
All alpha helical regions in OSM are highlighted in gray with the helices A (Y10-
I37), B (G66-Q90), C (E106-L131) and D (A159-S185) indicated. The cryptic 










Figure 2.2 SDS-PAGE analysis of OSM with or without the ‘AGA’ modification 
after subjection to thrombin cleavage. 





Figure 2.3 STAT3 activation in human Müller cells in response to stimulation with 




Table 2.1 Primers used for PCR amplification of hOSM gene and conducting 









AGR to AGA  
REV CTGAGAGGCCCCCGCGGCAGCCTTCGTG 
FWD CCCTGCCTCGGATGCTGCTCAGCGCGCGCTGGAGGGCTG FXXK to 
AXXA REV CAGCCCTCCAGCGCGCGCTGAGCAGCATCCGAGGCAGGG 
FWD GACTTAGAGCAGCGCCTCGGCGCGCCCCAGGATTTGGAGAGGT OSM-M1 
(Round 1) REV ACCTCTCCAAATCCTGGGGCGCGCCGAGGCGCTGCTCTAAGTC 
FWD CTCGGCGCGCCCTCTGGGCTGAAC OSM-M1  
(Round 2) REV GTTCAGCCCAGAGGGCGCGCCGAG 
FWD CAGCGCCTCGGCGGGGGCTCTGGGCTGAAC OSM-M2 
(Round 1) REV GTTCAGCCCAGAGCCCCCGCCGAGGCGCTG 
FWD CCTCGGCGGGGGCAACATCGAGGACTT OSM-M2 
(Round 2) REV AAGTCCTCGATGTTGCCCCCGCCGAGG 
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2.2. Recombinant protein expression and purification 
 
Expression and purification of hLIF, LIF05, OSM-WT* and its mutants OSM-M1 
and OSM-M2 was performed as described previously (Robinson et al. 1994a). 
Briefly, the proteins were expressed as glutathione-S-transferase (GST) fusion 
proteins in E. coli strain JM109. Cultures were grown in LB plus ampicillin 
(100μg/ml) at 37oC and 300 rpm until they reached midlog phase (A600 = 0.6). 
Isopropyl β-D-1-thyogalactopyranoside (IPTG) was then added to the culture to a 
final concentration of 0.1 mM and induction was carried out for additional 3 hrs at 
room temperature. Harvested bacteria are resuspended in lysis buffer (50 mM 
Tris-HCl (pH 7.5), 150 mM NaCl, 5 mM EDTA, 1% (v/v) NP-40, 5% (v/v) glycerol, 
and protease inhibitor cocktail (Calbiochem, San Diego, CA) and lysed using 
sonication at 60 kHz for 10 sec. The lysed solution is then centrifuged at 16000g 
for 20 min and the fusion protein in supernatant was recovered by affinity binding 
to a slurry of glutathione-Sepharose 4B beads (GE Healthcare, Uppsala, 
Sweden). Fusion protein bound beads were washed with 1X PBS three times 
with each for a duration of 30 min. Isolation of the desired protein was achieved 
by cleavage of the fusion protein with human thrombin (80 units for 1ml of beads) 
(Amersham Biosciences, Piscataway, NJ) in 1X PBS (pH 7.3) overnight at room 
temperature. Following cleavage, elution containing the cytokine was pooled with 
additional 4 batch washes (1X PBS, pH 7.3). Cleaved cytokines were further 
purified by fast protein liquid chromatography (FPLC) using a Mono-S (for LIF 
and LIF05) or MonoQ (for OSM and its mutants) ion exchange column 
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(Amersham Biosciences, Piscataway, NJ). Elution was carried out with a linear 
gradient of 0 – 1 M NaCl. Eluted fractions were analyzed using SDS-PAGE and 
the fractions containing enriched protein were pooled and concentrated by 
ultrafiltration (Millipore Corporation, Billerica, MA). Identity of the proteins was 
confirmed by mass spectrometry and concentrations were determined using BCA 
assay (Thermo Scientific, Rockford IL) using bovine serum albumin (BSA) as the 
standard.  
 
2.3. Circular Dichroism 
 
CD measurements were performed on a Jasco J-715 spectropolarimeter (Jasco, 
Easton, MA). Steady state spectra were recorded by scanning in the wavelength 
region between 200 and 250 nm with 0.1 cm pathlength and a 1 nm bandwidth at 
20oC. Spectra of blank buffer solutions acquired under identical conditions were 
used for background correction. Protein concentrations were maintained at 10 
μM in Dulbecco’s phosphate buffered saline (PBS) (9.33 mM potassium 
phosphate, 136 mM NaCl, 2.7 mM KCl, 0.6 mM MgCl2, 0.9 mM CaCl2). 
Estimation of the α-helical, β-sheet and loop content in the proteins was carried 




2.4. Cell culture and cytokine stimulation 
 
Müller cells and A375 melanoma cells were grown in DMEM-F12 and RPMI 1640 
respectively supplemented with fetal bovine serum (10%) (Invitrogen, Carlsbad, 
CA), penicillin (100 U/ml) and streptomycin (100 μg/ml) (Invitrogen, Carlsbad, 
CA). Cells were seeded in a 10cm tissue culture dish at a density of 100,000 
cells/plate and allowed to grow in a 37oC humidified atmosphere with 5% CO2. 
When the cells reached 80% confluency, the culture medium was changed to 
fresh serum free media (DMEM-F12 or RPMI 1640 supplemented with penicillin 
(100 U/ml) and streptomycin (50 μg/ml)). Serum starvation was carried out for 30 
mins before stimulation with desired doses of the cytokines for a period of 20 
mins. Following stimulation, cells were harvested for measurements of STAT3 
and ERK1/2 activation by Western blots. 
 
2.5. Cell proliferation 
 
To measure A375 melanoma cell proliferation, ATP activity of the viable cells 
was quantified using CellTiter-Glo Luminescent cell viability assay (Promega, 
Madison, WI). A375 melanoma cells were seeded in a 96 well plate at a density 
of 4000 cells/well in a total volume of 200 μl of RPMI 1640 (Invitrogen, Carlsbad, 
CA) supplemented with fetal bovine serum (10%), penicillin (100 U/ml) and 
streptomycin (100 μg/ml). Cells were then treated with different doses of OSM-
WT, OSM-M1 or OSM-M2 for desired duration immediately after seeding. Control 
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cells were treated with carrier solution, 1X PBS. Cell population in the wells was 
monitored using CellTiter Glo® Luminescent cell viability assay (Promega, 
Madison, WI) according to the manufacturer’s protocol. 
 
2.6. Animals and bright cyclic light preconditioning 
[Performed in Collaboration with Dr. Jiangang Wang] 
 
All procedures were approved and performed according to the guidelines 
provided by Institutional Animal Care and Use Committee (IACUC) of the 
University of Oklahoma Health Sciences Center. BALB/cJ mice (5-6 weeks of 
age) were obtained from Jackson laboratories and maintained in 60 lux cyclic 
light at cage level (12 hr ON: 12 hr OFF) for 7 days. Animals were then 
maintained in 600 lux cyclic bright light for preconditioning (12 hr ON: 12 hr OFF) 
for 6 days followed by a 4 day recovery period under normal cage room 













2.7. Bright Light Damage 
[Performed in Collaboration with Dr. Jiangang Wang] 
 
For bright light damage, unanesthetized mice were exposed to diffuse white 
fluorescent light maintained at 4000 lux at cage level for 4 hrs immediately after 
the bright light exposure (600 lux) on the 6th day of preconditioning (Figure 2.3). 
Control mice were maintained in normal cage room light condition (60 lux) prior 
to exposure to 4000 lux damaging light. After light exposure, all mice were 
allowed to recover for 8 hours in the dark and then kept in normal cage room 
lighting for 4 days before analysis by ERG and histology. 
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2.8. Real-time RT-PCR 
[Performed by Dr. Jiangang Wang] 
 
mRNA levels of selected genes were measured using real-time PCR with cDNA 
extracted from retinas as templates. Primers (Table 2.2) were designed using 
PrimerQuest software (Integrated DNA Technologies, Coralville, IA, USA) 
spanning the intron–exon boundary to amplify the corresponding mRNAs without 
amplifying potentially contaminating genomic DNA. Real-time PCR was carried 
out with the SYBR green PCR master mix (Bio-Rad Lab., Hercules, CA, USA) 
using the MyiQ Single-Color Real-Time PCR detection system (Bio-Rad Lab., 
Hercules, CA, USA) following the manufacturer’s instructions. Electrophoresis of 
PCR products was performed to identify that a single band of the correct size had 







Table 2.2 Forward and reverse primers used in RT-PCR analysis. (F – Forward, 
R – Reverse, bp – base pairs) 
 
Name   Sequences  (5' to 3') 
Product   
size (bp) 
 F TCACAGCCTGTACCTGAAGG 
RPL19 
 R  TCGTGCTTCCTTGGTCTTAG  
151 
 F TGAGATGCAGGGATTGTGCCCTTA 
LIF  
 R  AAATGAAGAGAGCATTGGCGCTGC 
187 
 F TTTGACCCTCAGTCTCCTCATCCT 
OSM 
 R  AGGGCTCCAAGAGTGATTCTGTGT 
134 
 F AAGACCACCAGACTGACTCCTCAA 
CT1 
 R  GCTGCACGTATTCCTCCAGAAGTT 
126 
 F ACGAGCCTGACTTCAATCCTCCT 
CLC 
 R  ACGCAAGTAACACAGGAGGTGACT 
147 
 F AGAGCAATCACCTCTGACCCTTCA 
CNTF 
 R  ATCTCACTCCAGCGATCAGTGCTT 
189 








2.9. Electroretinograms (ERGs) 
[Performed in Collaboration with Dr. Jiangang Wang] 
 
ERGs were recorded using a Colordome ERG instrument (Diagnosys, Littleton, 
MA) to measure the function of surviving photoreceptors. Analysis was carried 
out as described previously by Ueki et al. (149). Briefly, after an 8 hr dark 
adaptation, mice were deeply anesthetized with a single intraperitoneal injection 
of xylazine (7 mg/kg) and ketamine (40 mg/kg). Mice were then placed on a 37°C 
heating pad throughout the experiment. Pupils were dilated with tropicamide and 
phenylephrine. Full-field ERGs were recorded from both eyes using gold wire 
electrodes placed centrally on the cornea. A platinum reference electrode was 
attached in the mouth, and a platinum needle electrode in the tail served as a 
ground. Electrode positioning was monitored throughout the measurements 
using an infrared camera. A series of increasing flash intensities over a range of 
6 logarithmic units of intensity (0.001, 0.01, 1, 100, 200 and 400 cd.s/m2) were 
used (A light intensity of 1cd produces an illumination of 1 lux at a distance of 1 
meter from the light source). The amplitude of the a-wave was measured from 
the baseline to the trough of a-wave. After the ERG recording, retinas were 
harvested for histological analysis. 
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2.10. Intravitreal Injections 
[Performed in Collaboration with Dr. Jiangang Wang] 
 
Normal BALB/cJ mice were deeply anesthetized with a single intraperitoneal 
injection of xylazine (7 mg/kg) and ketamine (40 mg/kg). One micro liter of the 
cytokines or PBS (vehicle control) was injected into the vitreous chamber of the 
eye using a 36 gauge needle (World Precision Instruments, Sarasota, FL) 
through the temporal lymbus of the eye. For inhibition studies during bright cyclic 
light preconditioning, 8 μg of LIF05 were injected into the right eye of BALB/cJ 
mice in a volume of 1 μl PBS after 2 days of bright cyclic light preconditioning. 1 
μl of PBS was injected into the right eye which served as control. Following 
injection, the mice were returned to their cages for 4 more days of bright cyclic 
light preconditioning. After a total of 6 days of preconditioning, mice were 
euthanized and the eyes were enucleated and subjected to western blot analysis. 
 
 
2.11. Histological analysis 
[Eyes were processed by Dean A. McGee Eye Institute histological core facility 
and counting were done by Jiangang Wang and Srinivas Chollangi] 
 
Mice were euthanized with CO2 and the eyes were enucleated and marked with 
a green dye on dorsal surface to mark the superior hemisphere. Eyes were then 
fixed in PERFIX (20% isopropanol, 2% trichloroacetic acid, 4% 
paraformaldehyde, and 2% zinc chloride) overnight and placed in 70% ethanol at 
room temperature for 4 days followed by embedding in paraffin. Sagittal sections 
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through the center of the eye, including the optic disc, were cut at 5 μm 
thickness. After hematoxylin and eosin (H&E) staining, rows of photoreceptor 
nuclei were counted using light microscopy at nine equidistant points beginning 
at the optic nerve head toward both the inferior and superior retinal hemispheres.  
 
2.12. Western Blots 
For in vivo studies, retinas were harvested immediately after animals were 
euthanized while for cell culture studies, the cells were scraped off tissue culture 
plate in ice-cold PBS and centrifuged to get rid of the PBS. The retina or pelleted 
cells are then homogenized in a lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 5 mM EDTA, 1% (v/v) NP-40, 5% (v/v) glycerol, and protease inhibitor 
cocktail (Calbiochem, San Diego, CA)]. Protein content was measured using 
BCA protein assay (Pierce, Rutherford, IL). Total protein from each sample (15 
μg) was electrophoresed on 4-20% gradient SDS-polyacrylamide gels 
(Invitrogen, Carlsbad, CA), and transferred to nitrocellulose membranes (Bio-
Rad, Hercules, CA). The membranes were incubated in blocking buffer [5% BSA 
in TBST (20 mM Tris-HCl , pH 7.5, 100 mM NaCl, and 0.1% Tween-20)] for 1 h 
at room temperature, and then incubated overnight at 4˚C with rabbit polyclonal 
anti-phospho-STAT3 antibody or anti-phospho-ERK1/2 antibody (Cell Signaling 
Technology, Beverly, MA), in blocking buffer, followed by 1h incubation at room 
temperature with HRP-conjugated goat anti-rabbit secondary antibody 
(Amersham Biosciences, Piscataway, NJ). Signals were visualized using 
SuperSignal West Dura extended duration substrate (Pierce, Rutherford, IL) and 
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quantified by conventional digital image analysis using an ImageStation 4000R 
(Software: Kodak MI; Eastman Kodak, Rochester, NY). Blots were stripped and 
reprobed with anti-βactin (Abcam, Cambridge, MA) followed by appropriate 
secondary antibodies. Band intensities of pSTAT3 and pERK1/2 were normalized 
against the intensity of β-actin to account for loading variability. 
 
2.13. Surface Plasmon Resonance (SPR) 
[Experiments were performed by Srinivas Chollangi with guidance from ICX 
Technologies, Oklahoma City, OK] 
 
Kinetic parameters of the interactions between receptor domains and the 
cytokines LIF, OSMWT*, OSM-M1 or OSM-M2 were analyzed by surface 
plasmon resonance (SPR) using the SensiQ system (ICX Technologies, 
Oklahoma City, OK) as described by the manufacturer protocol. Briefly, a 
carboxyl sensor with two channels, was installed in SensiQ and allowed to 
thermally equilibrate for about 15 min. The channels were initially cleaned with a 
3 min injection of 0.1 M HCl. An activation solution of 2 mM 1–Ethyl–3-[3–
dimethylaminopropyl] carbodi- imide hydrochloride (EDC) and 0.5 mM N-
hydroxysulfosuccinimide (NHS) was prepared in deionized water immediately 
before injection. Activation solution was injected over both channels for 
approximately 3 min followed by a 10 min injection of 50 μg/mL cytokine (LIF, 
OSM-WT*, OSM-M1 or OSM-M2) in 10 mM acetate buffer pH 5.0 over channel 
1. Channel 2 did not receive any cytokines and thus served as a reference for 
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non-specific binding. Unreacted NHS esters were capped with a 3 min injection 
of 1 M ethanolamine, pH 8.0 over both channels. A concentration series of 
soluble LIFR, OSMR or gp130 (R&D Systems, Minneapolis, MN) in running 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3.4 mM EDTA, 0.005% Tween-20) 
were injected over both channels at a flow rate of 25 μl/min. Following a 
dissociation period of 3 min, the surfaces were regenerated by injecting 10 mM 
NaOH for 30 seconds. Rate constants for association (ka) and dissociation (kd) 
rates are derived by global analysis of the response curves fit to a 1:1 kinetic 
model (Equations 1 and 2) using QDat software (BioLogic Software, Ltd. 
Knoxville TN and Nomadics, Inc. Stillwater, OK) using 1:1 stoichiometry. 
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Where, RU – real time response units as measured by the SensiQ instrument; 
RUmax –the maximum response obtainable for a given concentration of the 
soluble receptor, t – time and Co – Concentration of the soluble receptor analyte 










2.14. Enzyme-linked immunosorbent assay (ELISA) 
ELISA was used to evaluate the equilibrium binding strength of the interaction 
between the cytokines and their receptors. This technique has traditionally been 
used as a sensitive method to quantify the binding affinites between two 
interacting proteins. However, unlike in SPR, ELISA involves immobilization of 
the proteins on a flat plastic surface driven by hydrophobic and ionic interactions. 
This might cause some distortion in the 3 dimensional structure of immobilized 
protein which leads to inaccuracies in the estimation of dissociation constants. It 
is thus important to bear in mind that the values estimated using this technique 
are to be used only for comparison between species but not as true equilibrium 
binding constants. The results obtained using this techinique will thus be 
presented as apparent equilibrium dissociation constants (KD,App). For direct 
interaction studies, cytokines (LIF, OSM-WT, OSM-M1 or OSM-M2) were 
immobilized on the 96 well ELISA plate by incubating the wells with 200 μl of 5 
nM cytokine solution in PBS, pH 7.4 overnight at 4oC. The wells were then 
blocked with blocking buffer (4% BSA in PBS) for 1 hour at room temperature. 
After washing with 250 μl of washing buffer (0.05% Tween-20 in PBS) 3 times, 
the cytokines were treated with a series of concentrations of soluble human LIFR 
(Catalog # 249-LR-050/CF, R&D Systems, Minneapolis, MN) or OSMR (Catalog 
# 4389-OR-050, R&D Systems, Minneapolis, MN) in 150μl of blocking buffer for 2 
hours. The wells were then incubated with 150 μl of polyclonal anti-hLIFR 
(Catalog # AF249-NA, R&D Systems, Minneapolis, MN) or anti-hOSMR (Catalog 
# AF662, R&D Systems, Minneapolis, MN) in blocking buffer for 1 hour followed 
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by incubation with 150 μl of HRP conjugated anti-mouse antibody (GE 
Healthcare, Uppsala, Sweden) in blocking buffer for 30 min. The wells were then 
washed 3 times with washing buffer and treated with 100 μl of chromogenic 
Slow-TMB® HRP substrate (Catalog # 34024, Thermo Scientific Fisher, 
Rockford, IL) for 15 min. The reaction was then stopped by adding 100 μl of 2M 
H2SO4 and the absorbance of each well at 450nm was read immediately using a 
UV detector (iMark® Microplate Reader, Biorad, Hercules, CA).  For interactions 
of higher order, soluble human gp130 (Catalog # 671-GP-100, R&D Systems, 
Minneapolis, MN) was immobilized on 96 well ELISA microplates by incubating 
the wells with 200 μl of 1 nM gp130 solution (in PBS, pH 7.4) overnight at 4oC. 
The wells were then blocked with 150 μl of blocking buffer (4% BSA in PBS) for 1 
hour at room temperature. After washing with 250μl of washing buffer 3 times, 
gp130 was treated with saturating amounts of the cytokines (500 nM hLIF, 200 
nM OSM-WT*, 200 nM OSM-M1 or 200 nM OSM-M2) in a volume of 150 μl of 
blocking buffer for a period of 2 hours. The cytokine solution was discarded and a 
series of concentrations of soluble human LIFR or OSMR in a final volume of 150 
μl blocking buffer were then added to the wells and the incubation was continued 
for another 1 hour. After washing with 250 μl of washing buffer 3 times the wells 
were then incubated with 150 μl of polyclonal anti-hLIFR or anti-hOSMR in 
blocking buffer for 1 hour. After 3 washes with 250 μl of washing buffer, the wells 
were then incubated with 150 μl of HRP conjugated anti-mouse antibody in 
blocking buffer for 30 min. The wells were then washed again 3 times with 
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washing buffer and treated with 100 μl of chromogenic Slow-TMB® HRP 
substrate for 30 min. The reaction was then stopped by adding 100 μl of 2M 
H2SO4 and the absorbance of each well at 450 nm was read using a UV detector. 
Equilibrium dissociation constants (KD) are estimated by non-linear curve fitting to 
the optical density (OD) values plotted against the concentrations of soluble 
receptor using GraphPad Prism software (GraphPad Software, La Jolla, CA). 
 
2.15. Synthesis of PEG hydrogels 
Diacrylated poly(ethylene glycol) (PEG) macromer with a molecular weight of 
5000Da was purchased from Laysan Bio, Inc (Catalog # ACRL-PEG-ACRL-
5000, Laysan Bio, Inc. Arab, AL) (Figure 2.6). For hydrogel preparation, the PEG 
macromer was allowed to equilibrate to room temperature and then dissolved in 
50 mM phosphate buffer solution (PBS) (pH 7.4) to a final macromer weight 
percentage of 10%, 20%, 30%, 40% or 50%. 10μg of desired protein (hOSM or 
BSA) and photoinitiator, Irgacure 2959 (final concentration of 0.1 wt%) (Catalog # 
410896, Sigma, St. Louis MO) were also added to the macromer solution and the 
mixture was agitated well until all the components were dispersed 
homogeneously in the solution. 10 μl of the final solution is transferred into a 
transparent disc shaped mould and exposed to UV light at a wavelength of 365 
nm (Kodak GL100, Eastman Kodak, Rochester, NY) for approximately 7 minutes 
to ensure complete polymerization of the functionalized macromer (Figure 2.7). 
After polymerization, solidified gel was carefully removed from the mold and used 
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for swelling and drug release studies. Hydrogels made with no protein inside 





Figure 2.6 Chemical structures of poly(ethylene glycol) (PEG) and poly(ethylene 






Figure 2.7 Schematic representation of photopolymerization. 
(PEG 5000 DA – Diacrylated PEG with an average molecular weight of 5000 Da; 
OSM –Oncostatin M; I--I 2959 – commercial photoinitiator used to trigger the 
polymerization reaction). Also shown in the inset at right hand corner is the 
picture of a hydrogel obtained after polymerization and drying under vacuum 
overnight.  
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2.16. Theoretical Estimation of Drug Release 
 
A disc shaped non-degradable hydrogel with high aspect ratio was considered 
for all the experiments and the drug was assumed to be dispersed 
homogeneously throughout the gel (Figure 2.8). Three boundary conditions were 
used to solve the model: (i) concentration of diffusible species (i.e. free drug) at 
the gel boundary (x =  L) is zero (ii) concentration of the diffusible species 
inside the hydrogel is homogenous and constant Co at time t = 0 and (iii) diffusion 
is symmetric about the center of the gel (x = 0). A high aspect ratio leads to the 
valid assumption of unsteady state one-dimensional diffusion from either face of 
the gel according to Fick’s second law as given by the equation: 
±










∂                                         
C is the concentration of drug inside the gel at time t and position x, and Dg is the 
diffusion coefficient of the drug inside the swollen hydrogel. The hydrogel is non-
degradable and thus the structural properties of the hydrogel and thus diffusion 
coefficient of the drug will stay constant throughout the release process. 
However, if the network were to be degradable, both the mesh size (ξ) and the 
diffusivity of the drug in hydrogel (Dg) change with respect to time. Applying the 
above boundary conditions, one can solve the equation to obtain the 
concentration distribution of drug inside the hydrogel with respect time (t) and 
position (x). Also, using this information, the percent release of drug from the 





Figure 2.8 Schematic representation of a lateral section of circular disc uniformly 
dispersed with drug (shown in blue color) at a concentration Co. 
 
Boundary conditions are as described on the right side panel. Diffusion is 
symmetric about the central plane of the hydrogel i.e. x=0 
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2.17. Evaluation of Drug Release – In vitro 
 
Immediately after photopolymerization, drug encapsulated hydrogels were 
weighed and then transferred to a 1 ml sink of 50 mM phosphate buffered saline. 
The saline along with hydrogel is continuously shaken throughout the experiment 
to maintain the boundary conditions. 10 μl samples of the supernatant solution 
were taken out at regular intervals and replaced with 10 μl of fresh PBS. Samples 
taken out were assayed for protein concentration using BCA assay and the 
resulting values were used to calculate the total amount of drug released from 
the hydrogel until that time point.  
 
 
2.18. Evaluation of Drug Release – In Vivo 
 
After polymerization, the drug encapsulated hydrogels are maintained under 
vacuum over night until they are completely dry and solid. Normal BALB/cJ mice 
were deeply anesthetized with a single intraperitoneal injection of xylazine (7 
mg/kg) and ketamine (40 mg/kg). A small 2 – 3 mm width incision is then made 
on the superior side of the conjunctival membrane. The dried hydrogel is then 
implanted sub-conjunctivally and slid to the posterior side of the eye (Figure 2.9). 
The mice were then placed back into their cages and maintained under normal 
cage room light conditions. At desired time points, the mice were euthanized with 
CO2 and the eyes were enucleated immediately. Retinas were then harvested for 





Figure 2.9 Schematic representation of sub-conjunctival hydrogel implantation in 
a mouse eye 




2.19. Statistical Analysis 
 
All statistical analyses are done using SigmaStat 3.10 (Systat Software, Inc. 
Richmond, CA). Results are expressed as mean ± standard deviation (SD). 
Differences between two groups were assessed using either paired or unpaired t-
tests while differences between more than two groups were assessed using 
Analysis of Variance (ANOVA) followed by Holm-Sidak post hoc test. A p-value 
less than 0.05 was considered significant. 
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3. RESULTS AND DISCUSSION 
 
 
3.1. Preconditioning-Induced Protection from Oxidative Injury 
is Mediated by Leukemia Inhibitory Factor Receptor (LIFR) 
and its Ligands in the Retina 
3.1.1. Introduction 
 
Photoreceptor cells are the sensory neurons in the eye that absorb light to initiate 
vision (See figure 3.1 for schematic representation of cells in retina). Since these 
cells are postmitotic, loss of photoreceptors results in permanent blindness. 
Insults that can kill photoreceptors include genetic mutations, mechanical injury 
and oxidative damage (146,295-297). Prolonged bright light exposure can also 
induce oxidative damage which, when severe, kills photoreceptors (298,299). 
However, under such unfavorable conditions, retinal cells initiate a response to 
rescue photoreceptors by recruiting or secreting a variety of antioxidants, 
cytokines and/or neurotrophic factors (153,298,300-303). This has been clearly 
demonstrated in models where exposure to subtoxic levels of stress (e.g., bright 
cyclic light) induced changes in retinal tissue that protect photoreceptors from a 










Factors that were shown to be upregulated under oxidative stress include basic 
fibroblast growth factor (bFGF), CNTF, brain derived neurotrophic factor (BDNF), 
LIF, and CLC (134,296,300,304). While these are hypothesized to play a role in 
preconditioning-induced endogenous neuroprotection, it has not yet been 
demonstrated which factors or receptors are essential for the protection. 
Intriguingly, among the upregulated molecules LIF, CNTF, and CLC belong to the 
same family and signal through heterodimerization of leukemia inhibitory factor 
receptor (LIFR) and glycoprotein 130 (gp130). Since these ligands and receptors 
are functional in the retina (149,302,305), our hypothesis is that activation of 
LIFR:gp130 complex plays an essential role in preconditioning-induced 
endogenous protection of retinal photoreceptors. This hypothesis predicts that 
inhibiting the activation of these receptors during stress would make the 
photoreceptor cells more susceptible to oxidative damage. LIF05, a mutant LIF 
molecule, antagonizes LIF, CNTF, CT-1 and CLC activities by competitively 
binding and blocking the LIFR dimerization with gp130 (48,294). In this study, we 
tested our hypothesis by delivering LIF05 during preconditioning. The data show 
that inhibiting LIFR activation blocks the protective effects of preconditioning, 




3.1.2.1. Preconditioning-Induced Protection 
 
Functional and morphological evaluation of photoreceptor cell protection by 
bright cyclic light preconditioning was carried out using ERG and quantitative 
histological analysis. BALB/cJ mice, with or without prior bright cyclic light 
preconditioning were subjected to severe light stress before returning them to 
room light conditions for 4 days of recovery followed by ERG and histological 
analysis. Figures. 3.2A and 3.2B show amplitudes of ERG a-waves in response 
to different intensities of light flashes. a-waves represent the electric response 
generated in photoreceptors and thus serve as a measure of photoreceptor 
function in response to light. As expected, mice that were exposed to severe light 
stress without preconditioning exhibited almost complete loss of photoreceptor 
function. However, mice that were preconditioned with bright cyclic light (600 lux; 
6 AM to 6 PM for 6 days) prior to the severe light stress were able to retain 
almost 83% of their retinal function. Figures 3.2C and 3.2D show representative 
sections of the superior retina and quantitative analysis of photoreceptor 
numbers in the outer nuclear layer (ONL), respectively. As reflected in the ERG 
analysis, animals that were subjected to light stress without preconditioning 
exhibited severe photoreceptor degeneration. Compared to normal, undamaged 
retina that contain 10–11 rows of photoreceptor nuclei in the ONL, these animals 
retained only 1–2 rows of photoreceptor nuclei following bright light exposure.  
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Figure 3.2 Functional and morphological evaluation of preconditioning-induced 
protection of retinal photoreceptors 
A) Representative ERG traces and B) a-wave amplitudes of BALB/cJ mice that 
have been light damaged (LD) (4000 lux for 4 h) with (○) or without (□) prior 
bright cyclic light preconditioning (600 lux; 6 AM to 6 PM) for 6 days. Control 
eyes are represented in solid squares (■). n=6; value = mean ± SD. (*p<0.001, 
vs. LD eyes, paired t-test). C) Representative sections and D) quantification of 
number of rows of photoreceptor nuclei in the outer nuclear layer (ONL) along 
the vertical meridian of the retina. n=6; value = mean ± SD (*p<0.001, vs. LD 
eyes, paired t-test). ONL – Outer nuclear layer; INL – Inner nuclear layer; GCL – 
Ganglion cell layer; ON – Optic nerve. [Experiments were performed in 
collaboration with Dr. Jiangang Wang] 
 97
However, in animals that were subjected to bright cyclic light preconditioning, the 
degeneration was modest, as mice retained 9–10 rows of photoreceptor nuclei in 
spite of the severe light stress. These data demonstrate that preconditioning with 
sub-toxic light stress protects the retina from a subsequent dose of lethal light 
damage. 
 
3.1.2.2. Expression of neuroprotective factors during preconditioning 
 
Previous reports have shown that injury or stress in the retina can induce 
expression of neuroprotective factors (150,296,303,304,306,307). To determine 
which factors could be responsible for preconditioning-induced protection in our 
model, we measured gene expression changes of neuroprotective factors that 
include LIF, CNTF, OSM, CT-1, CLC and BDNF. Ribosomal protein RPL19 was 
used as control. Results show that LIF, OSM, CT-1 and CLC exhibit a strong 
upregulation (166, 74, 21 and 47-fold respectively) with bright cyclic light 
preconditioning in a time-dependent manner (Figure 3.3A). Surprisingly, unlike 
reported results in rats (153) we did not observe any upregulation of CNTF. 
BDNF, another neuroprotective factor, exhibited an 11-fold increase in its levels 
by the end of the 6th day of preconditioning. We then tested whether this strong 
upregulation of LIF, OSM, CT-1, CLC and BDNF is reflected at a functional level 
by measuring activation of a common downstream signaling molecule, STAT3. 
Results show a robust time-dependent activation of STAT3 with bright cyclic light 
preconditioning (Figures 3.3B and 3.3C). STAT3 reached peak activation by the 
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end of 4 days of preconditioning and remained elevated with 6 days of 
preconditioning. Activation of STAT3 could be mediated by LIFR:gp130 
heterodimer (triggered by LIF, CT-1, CLC (21,22,308)), OSMR:gp130 
heterodimer (triggered by OSM (309)) or the TrkB receptor (triggered by BDNF 
(310)). Therefore, we tested whether LIFR:gp130 activation is essential for 








Figure 3.3 Preconditioning with bright cyclic light leads to strong upregulation of 
neuroprotective factors. 
A) Time-dependent quantitative evaluation of cytokine mRNA upregulation using 
real time RT-PCR in response to bright cyclic light preconditioning (600lux; 6AM 
to 6PM). Members of IL-6 family cytokines (LIF, OSM, CT-1 and CLC) are 
upregulated 166, 74, 21 and 47 fold in response to bright cyclic light 
preconditioning. While CNTF did not exhibit a similar upregulation, BDNF 
exhibited an 11-fold increase in its mRNA levels by the end of the 6th day of 
preconditioning. Ribosomal protein RPL19 served as a control. n=4; value = 
mean ± SD. (*p<0.01, paired t-test). B) Representative Western blots and C) 
quantification of STAT3 activation. n=3; value = mean ± SD. We observed a 
robust preconditioning-dependent STAT3 activation which reached peak 
activation by the end of 4 days of preconditioning and remained elevated 
throughout the preconditioning exposure. [Experiments were performed in 
collaboration with Dr. Jiangang Wang] 
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3.1.2.3. Antagonism of LIFR attenuates preconditioning-induced STAT3 
activation 
 
hLIF has two active sites, site II and site III that bind to gp130 and LIFR 
respectively (21,22,48,64,311,312). LIF first binds LIFR and then recruits gp130 
forming a high affinity heterodimer complex (21,23). This heterodimerization 
leads to the activation of Jak mediated STAT3 pathway (13,14,313,314). Hudson 
et al. (48,294) have mutated the gp130 binding sites on hLIF generating the 
antagonist LIF05, which binds LIFR but can no longer bind gp130 to activate the 
STAT3 pathway. It thus acts as a competitive inhibitor for all cytokines that recruit 
LIFR. If injected in vivo, LIF05 is predicted to block the activities of LIFR 
activating cytokines LIF, CNTF, CT-1 and CLC. Unlike in humans, mOSM can 
signal only through OSMR:gp130 (type II receptor complex) but not LIFR:gp130 
(type I receptor complex) (23,309). Thus, LIF05 cannot antagonize OSM 
activities in mice. To determine whether LIFR activation was responsible for 
preconditioning-induced STAT3 activation we injected 2, 5 or 8 μg of LIF05 into 
the right eyes of mice after 2 days of preconditioning while left eyes were injected 
with PBS to serve as controls. Following injection, mice were preconditioned 4 
additional days in bright cyclic light. After a total of 6 days of preconditioning, 
STAT3 activation was measured using Western blot analysis. Figure 3.4 shows 
that 2 μg of LIF05 was able to inhibit 45% of the preconditioning-induced STAT3 
activation while 5 μg and 8 μg of LIF05 were able to block the activation by about 
60% and 70%, respectively. This clearly demonstrates that LIF05 is able to inhibit 
the preconditioning-induced STAT3 activation in a dose-dependent manner by 
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Figure 3.4 LIF05 inhibited preconditioning-induced STAT3 activation. 
A) After 2 days of bright cyclic light preconditioning (600lux; 6Am to 6PM), mice 
were injected with PBS in the left eye (control) and LIF05 (2μg, 5μg or 8μg) in the 
right eye and returned to their cages for additional bright cyclic light 
preconditioning. After the 6th day of preconditioning, retinas were harvested and 
STAT3 activation was analyzed using Western blotting. PBS injected eyes 
without preconditioning served as controls for basal levels of STAT3 activation. 
PC – Preconditioning. B) Bands were quantified by conventional digital image 
analysis using a KODAK Image Station 4000R. n=3; value = mean ± SD. 
(*p<0.05, vs. PBS injected eyes with preconditioning, one way ANOVA and post 
hoc Holm-Sidak test for multiple comparisons) [Experiments were performed in 
collaboration with Dr. Jiangang Wang] 
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antagonizing LIFR activation. Injection of 12 μg LIF05 did not further decrease 
the STAT3 activation compared to 8 μg LIF05. This residual activation could be 
due to other factors including OSM and BDNF which LIF05 cannot antagonize. 
Clearly LIFR activation is playing an essential role in preconditioning-induced 
STAT3 phosphorylation. Surprisingly, preconditioning also induced a 2-fold 
increase in total STAT3 levels (Figure 3.3B). This increase was not reduced by 
LIF05 (Figure 3.4) suggesting that the increase in total STAT3 is a result of 
activation of pathways independent of LIFR such as OSMR or TrkB. 
 
3.1.2.4. Antagonism of LIFR blocks preconditioning-induced protection 
 
In order to assess the role of LIFR in preconditioning-induced protection, we 
injected LIF05 during bright cyclic light preconditioning and determined whether 
blocking LIFR abolishes the preconditioning-induced protection. After 2 days of 
preconditioning, PBS or LIF05 (8 μg) were injected intravitreally and the mice 
were returned to their cages for additional bright cyclic light preconditioning. After 
the 6th day of preconditioning (i.e., 4 days after injection), animals were 
subjected to severe light stress (4000 lux for 4 h; 6 PM to 10 PM) immediately 
after the bright light adaptation and allowed to recover from the stress for 4 days 
under normal cage room light conditions (60 lux; 6 AM to 6 PM). Following 
recovery, animals were subjected to functional analysis using ERG and the eyes 
were harvested immediately for quantitative histological analysis. Figures 3.5A 




Figure 3.5 LIF05 inhibited preconditioning-induced protection of retinal 
photoreceptors. 
A)  Representative ERG traces and B) quantification of a-wave amplitudes of 
BALB/cJ mice that are light damaged (LD) (4000lux for 4h) with (○,▲,♦) or 
without (Δ, □) prior bright cyclic light preconditioning (600lux; 6AM to 6PM for 6 
days). Compared to uninjected eyes with preconditioning (○), LIF05 injected eyes 
lost 44% at the brightest flash intensity. n=6; value = mean ± SD (*p<0.05, vs. 
PC+LD eyes, paired t-test). C) Representative sections from superior retina and 
D) quantification of the number of rows of photoreceptor nuclei in the outer 
nuclear layer (ONL) along the vertical meridian of the retina. n=6; value = mean ± 
SD (*p<0.05, vs. PC+LD eyes, paired t-test). ONL – Outer nuclear layer; INL – 
Inner nuclear layer; GCL – Ganglion cell layer; ON – Optic nerve. [Experiments 
were performed in collaboration with Dr. Jiangang Wang] 
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of the retinal function by 44% (compared at the brightest flash intensity, 
LIF05+PC+LD vs. PC+LD). This decrease in retinal function is caused by 
reduced protection of photoreceptors in the presence of LIF05 since we observe 
a significant increase in photoreceptor cell loss following light stress in LIF05 
injected eyes (Figures 3.5C and 3.5D, 10 layers in PC+LD vs. 6 layers in 
LIF05+PC+LD). While PBS injection caused a slight decrease in the retinal 
function (Figures 3.5A and 3.5B), it did not lead to a significant decrease in 
photoreceptor survival (Figures 3.5C and 3.5D). The mechanism for the loss of 
function in PBS injected eyes without a loss in photoreceptor cells is currently 
unknown, but similar results have been observed in the absence of light stress 
where PBS injection causes a transient reduction in retinal function without 
causing any cell death. As expected, PBS injected control eyes that were 
subjected to light damage without preconditioning (PBS+LD), exhibited dramatic 
loss in retinal function and the photoreceptors, but was slightly protective 
compared to non-injected light damaged eyes (LD). Together, these results 
clearly suggest that blocking LIFR activation during preconditioning attenuates 
the endogenous protective mechanism triggered by bright cyclic light 
preconditioning. 
 
3.1.2.5. Effect of LIF05 on normal retinal function 
 
In order to rule out the possibility that injection of LIF05 itself kills photoreceptors, 
we injected 8 μg of LIF05 intravitreally into a normal BALB/cJ mice and 
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measured the retinal function and morphology using ERG and histological 
analysis 8 days after injection. LIF05 did not induce any change in retinal function 
or morphology compared to PBS control (Figures 3.6A and 3.6B). This suggests 
that LIF05 had no toxic effects on retinal function and morphology up to dosages 





Figure 3.6 Evaluation of LIF05 toxicity towards retinal function and morphology 
A) Representative ERG traces and B) quantification of a-wave amplitudes of 
BALB/cJ mice 8 days after injection with PBS (■) or LIF05 (◊). C) Representative 
sections from superior retina and D) quantification of the number of rows of 
photoreceptor nuclei in the outer nuclear layer (ONL). n=3, value = mean ± SD.  
ONL – Outer nuclear layer; INL – Inner nuclear layer; GCL – Ganglion cell layer; 
ON – Optic nerve. [Experiments were performed in collaboration with Dr. 
Jiangang Wang] 
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3.1.2.6. LIF05 inhibits LIF induced STAT3 activation 
 
To demonstrate that LIF05 functions as an antagonist specifically against LIFR 
ligands, we intravitreally injected 0.1 μg of LIF, a quantity that was previously 
shown to activate STAT3 in the retina (149), with or without the antagonist LIF05. 
PBS injected eyes served as negative controls. Two days after injection, we 
measured the levels of STAT3 activation using Western blot analysis. While 2 μg 
of LIF05 was able to inhibit 50% of the LIF induced STAT3 activation 5 μg and 8 
μg of LIF05 were able to inhibit STAT3 activation by 60% and 90% respectively 
(Figure 3.7). This clearly demonstrated that LIF05 inhibits LIFR activation by 
agonists in vivo in a dose-dependent manner. However, significantly larger 
amounts of LIF05 were needed (8μg) to effectively antagonize smaller doses of 
LIF (0.1 μg). To determine why such large quantities of antagonist are needed, 









Figure 3.7 LIF05 inhibits LIF stimulated STAT3 activation in vivo. 
A) 0.1 μg of LIF was injected intravitreally with 0, 2, 5, or 8 μg of the antagonist 
LIF05. After 2 days of injection, retinas were harvested and STAT3 activation 
levels were analyzed using Western blot analysis. Staining for total STAT3 and 
β-actin served as loading controls. A) Bands were quantified by conventional 
digital image analysis using a KODAK Image Station 4000R. n=3; value = mean 
± SD (*p<0.05, vs. LIF only injected eyes (LIF 0.1 μg), one way ANOVA and post 
hoc Holm-Sidak test for multiple comparisons). [Experiments were performed in 
collaboration with Dr. Jiangang Wang]. 
 110
3.1.2.7. LIF forms a high affinity stable complex with LIFR and gp130 
 
Figures 3.8A and 3.8B show the SPR analysis of LIFR interaction towards LIF 
and LIF05. Recombinant soluble LIFR and gp130 were injected over immobilized 
GST-LIF or GST-LIF05 to determine the kinetic rate constants for association 
and dissociation. Results show that both LIF and LIF05 display high affinity 
towards LIFR, exhibiting fast association and dissociation rates yielding an 
equilibrium dissociation constant (KD) of 2.93nM and 4.72nM respectively (See 
Table 3.1). Also, LIF displays a weaker affinity towards gp130 exhibiting a slow 
association and fast dissociation from gp130 compared to LIFR yielding an 
equilibrium dissociation constant of 74.57nM (See Table 3.1).  Because of its 
mutations, as expected, LIF05 did not exhibit any affinity towards gp130 (Figure 





Figure 3.8 Kinetic analysis of LIFR and gp130 interaction towards LIF and LIF05 
Soluble LIFR at concentrations of 1.5 nM, 3 nM, 6.25 nM, 12.5 nM, 25 nM or 50 
nM were injected over an SPR sensor chip with anti-GST immobilized A) GST-
LIF or B) GST-LIF05 at flow rates of 25 μl/min. Responses obtained were 
corrected for background signal using a control flow cell. Association and 
dissociation rates are derived by global analysis of the response curves fit to a 
1:1 kinetic model using QDat software (BioLogic Software, Ltd. Knoxville TN and 
Nomadics, Inc. Stillwater, OK) using 1:1 stoichiometry. Models are indicated in 
smooth gray line overlaid over response curve traces. Soluble gp130 (100 nM) 
was injected over C) GST-LIF or D) GST-LIF05 either as a mixture with soluble 
LIFR (10 nM) or separately at flow rates of 25 μl/min. [Experiments were 




Table 3.1 Comparison of association (ka), dissociation (kd) and estimated 




 LIFR (analyte)  gp130 (analyte) 
ka (M-1s-1) kd (s-1) KD (nM)  ka (M-1s-1) kd (s-1) KD (nM)  
LIF 3.66 x 105 1.07 x 10-3 2.93  0.72 x 105 5.37 x 10-3 74.57 












Previous work and our results show that preconditioning with moderate light 
stress protects retinal photoreceptors from a subsequent exposure to damaging 
light (151-153,298). However, the mechanism for this inducible protection is far 
from fully understood. Previous studies have shown that exposure to light stress 
results in a strong upregulation of CNTF, bFGF (in rats), LIF and CLC (in mice) 
(153,304). Separate studies have also shown that injection of these factors 
(CNTF, LIF or bFGF) in the absence of preconditioning can also protect 
photoreceptors from light damage (148,149,296) suggesting that their 
upregulation during stress is functionally connected to protection. In addition, 
other reports in rats have shown that photoreceptors near sites of mechanical 
injury are protected from a subsequent light stress. This protection was again 
accompanied by increases in the levels of bFGF and CNTF at the site of injury 
(301,303,306). These findings clearly indicate that the retina has a self defense 
mechanism that helps it cope with unfavorable changes in the retinal tissue 
environment. However, the multiple factors that are upregulated can activate a 
variety of receptors and signaling pathways. It is thus far not clear, which of these 
pathways are primarily involved in the endogenous protective mechanism.  
 
In our experiments with the bright cyclic light preconditioning model, we observed 
a strong upregulation of neuroprotective factors LIF, OSM, CT-1 and CLC which 
recruit either LIFR:gp130 or OSMR:gp130 complex for signaling. However, unlike 
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in rats, we did not notice any similar upregulation of CNTF in mice in response to 
bright cyclic light preconditioning. A similar observation was made by Samardzija 
et al. (304). This difference in the type of neuroprotective factors that regulate 
endogenous protection is probably attributed to species differences. Intriguingly 
LIF, CNTF, OSM, CT-1, and CLC, all belong to the same IL-6 family of cytokines 
that utilize gp130 receptor complexes to elicit similar and overlapping 
physiological responses mediated by STAT3 activation (13,14). So, the final 
neuroprotective responses in both mice and rats could be very similar. Also, we 
observed a modest increase in another neuroprotective factor, BDNF which 
signals via TrkB receptors. The robust activation of STAT3 in a preconditioning-
dependent manner suggests that these expressed cytokines (LIF, OSM, CT-1 
and CLC) are functional and activating the signal transducing receptor gp130 
leading to STAT3 phosphorylation. We thus hypothesized that activation of 
LIFR:gp130 complex plays an essential role in preconditioning-induced 
protection of retinal photoreceptors.  
 
In mice LIF, CNTF, CT-1 and CLC bind to LIFR and gp130 to induce signaling 
while OSM utilizes OSMR and gp130. Blocking LIFR activation during 
preconditioning significantly attenuated induced STAT3 activation and protection 
of photoreceptor cells in the retina. These results confirm that LIFR is a vital part 
and plays an essential role in the endogenous protective mechanism inside the 
retina leading to photoreceptor survival and that the protection is likely mediated 
by its ligands LIF, CT-1 or CLC. In agreement with our observations, Joly et al., 
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(150) have recently shown that LIF knockout mice have accelerated 
photoreceptor degeneration in a mouse model of inherited autosomal dominant 
retinitis pigmentosa. Together, these results demonstrate an important role for 
LIFR in an endogenous protective mechanism. Our previous observations that 
intravitreal LIF injections can lead to signal transduction in photoreceptors 
demonstrates that LIF can penetrate retinal cell layers to directly activate 
LIFR/gp130 complexes on photoreceptors (149). The formation of a stable 
complex between LIF, LIFR and gp130, and persistent robust signal transduction 
suggests that this would make an effective ligand–receptor system for induction 
of long-term protection from a chronic stress.  
 
Finally, the observation that LIF05 did not induce photoreceptor cell death under 
normal conditions (Figure 3.6) together with the evidence that there is no STAT3 
activation at such conditions (Figures 3.3B and 3.3C, 0 days) suggests that LIFR 
is not active and its activation is not required for the survival of photoreceptors at 
physiological conditions. It is only under stressed conditions that this receptor is 
activated and leads to photoreceptor survival via STAT3 mediated survival 
pathways (315). Endogenous inducibility, cooperative binding and prolonged 




3.2. A Unique Loop Structure in Oncostatin M Reduces 
Binding Affinity Towards Oncostatin M Receptor and 




IL-6 family cytokines (IL-6, IL-11, LIF, OSM, CNTF, CT-1 and CLC) possess a 
typical “four-α-helix bundle” like structure and act on their target cells by forming 
a multimeric receptor complex which includes the common receptor gp130 (13). 
Extensive mutagenesis studies revealed that these cytokines interact with the 
receptor-chains through three distinct binding sites referred to as sites I, II and III 
(316,317). Cytokines requiring a co-receptor chain (IL-6, IL-11, CNTF, and CT-1) 
first bind to the co-receptor (IL-6R, IL-11R, or CNTFR) through the binding site I 
(19,28-30,49). The glycoprotein gp130 always interacts through binding site II 
and, depending on the cytokine, the third binding site (site III) is used for 
recruitment of LIFR, OSMR or a second gp130 molecule (18,21,23,26,27,50). 
Research has shown that a conserved ‘FXXK’ motif at the core of site III is 
essential for all LIFR binding proteins for their interaction with LIFR (4,47,48). 
After recruiting the required receptors, these cytokines signal via activation of 
Jak/STAT (janus kinase/signal transducer and activator of transcription) and 
MAPK (mitogen activated protein kinase) pathways (52,313,318,319). 
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Among its family members, OSM resembles LIF most closely both in structure 
and function (320). The gene encoding for OSM, located on human chromosome 
22q12, is only 20 kb away from LIF suggesting that these two genes evolved by 
gene duplication (320-323). In spite of the striking similarities, OSM differs from 
LIF in its receptor binding. While LIF first binds to leukemia inhibitory factor 
receptor (LIFR) and then recruits glycoprotein 130 (gp130) for its signal 
transduction (5,21,23,48), OSM first binds gp130 and then recruits LIFR 
(4,5,21,23,48,50,309,324). In addition, OSM can bind to gp130 and then recruit a 
unique receptor named Oncostatin M receptor (OSMR) forming a distinct 
signaling complex (23,50,309). Our aim was to identify the structural features on 
OSM that result in its unique ability to bind OSMR and the features that result in 
its higher affinity towards gp130 than towards LIFR or OSMR. Based on the 
structural alignments, we have identified a helical loop on OSM between its B 
and C helices that is unique to OSM and not found on LIF or any other IL-6 family 
cytokine (Figure 3.9). Using wild type and mutant OSM molecules that have 
shortened BC loops we show that the loop appears to present a steric hindrance 
for LIFR and OSMR, thus lowering the affinity for either receptor. Cytokines with 
deletions in the BC loop were able to activate LIFR:gp130 and OSMR:gp130 
receptor complexes at 3 fold lower concentrations than the native OSM. Kinetic 
analysis of the ligand-receptor interactions show that improved activation is a 
consequence of increased affinity for the LIFR without altering the affinity for 
gp130. Together, these results suggest that the BC loop modulates OSM’s 
affinity towards LIFR by presenting a steric hindrance for their interaction. Our 
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studies also indicate that the BC loop does not play a role in OSM’s unique ability 




3.2.2.1. Structural analysis of hLIF and hOSM: Identification of the BC loop.  
 
To determine the structural differences that might account for receptor specificity, 
we aligned the crystal structures of hOSM (PDB ID: 1EVS) onto hLIF (PDB ID: 
1EMR) based on the trace of α-carbons using Delano Scientific’s PyMol 
molecular viewer (http://pymol.org) (Figure 3.9). The alignment of the backbone 
structures fit well with a relatively low RMSD value of 4.342. The active sites II 
and III on both molecules exhibited good conservation in structural orientation. 
Previous reports showed that the FXXK motif is essential for OSM’s interaction 
with both LIFR and OSMR (4,325). In spite of having a similar FXXK motif, other 
LIFR interacting cytokines LIF, CNTF, CT-1 and CLC however cannot activate 
OSMR (5). This suggested that the difference in receptor specificity between 
hOSM and other LIFR activating cytokines is the result of structural differences 
between these ligands in the vicinity of the core FXXK motif (4). One of the 
obvious structural differences in the alignments is the presence of an additional 
helical loop between its B and C helices in OSM that is not present in LIF (Figure 
3.9). This BC loop is positioned in close proximity to the FXXK motif in active site 
III. Based on the crystal structures solved for LIF in complex with LIFR (PDB ID: 
2Q7N) or gp130 (PDB ID: 1PVH), we have generated a model for the trimeric 
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complex of LIF:LIFR:gp130 using PyMol (Figure 3.9D). When OSM was 
superimposed over LIF in this trimeric model, the BC loop on OSM again stands 
out as a unique motif at the receptor binding interface of OSM. This suggested 
that the BC loop is possibly playing an essential role in recognizing OSMR.  
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Figure 3.9 A, B) Crystal structures of LIF (PDB: 1EMR) and OSM (PDB: 1EVS) 
with their active sites and helices A, B, C and D identified. 
Both structures have an “up-up-down-down” topology with the N-terminus and C-
terminus indicated. Also identified is the helical loop on OSM between its B and 
C helices. C) Shown on right is the alignment of OSM structure onto LIF based 
on the α-carbon trace; RMSD = 4.342. While the overall structures and the active 
site orientation on LIF and OSM show remarkable conservation, the BC loop on 
OSM clearly projects out as a unique feature on OSM. This loop lies in close 
proximity to the active site III containing “FXXK” motif. D) Also shown on the 
bottom panel is the three dimensional model for LIF in complex with LIFR and 
gp130 in presence of OSM overlaid on LIF. Again, the BC loop on OSM clearly 
projects out into the space of LIFR suggesting a possible role for the loop in 
OSM’s unique ability to recognize OSMR. 
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To test this hypothesis, we generated substitution mutations in OSM that either 
remove or shorten the length of this BC loop. Wild type OSM contains 12 amino 
acids in the BC loop region. Using site directed mutagenesis, we have deleted or 
modified the amino acids in this region to generate OSM molecules that 
contained 7, 4 or 0 amino acids. Shown in figure 3.10 are the sequences of 
mutant OSM molecules with truncated BC loops (OSM-M1, OSM-M2 and OSM-
M3) in comparison to the wild-type* OSM (OSM-WT*). Glycines (G) were 
incorporated into OSM-M1 and OSM-M2 to induce flexibility into the loop region 
thus minimizing the impact of this BC loop modification on the overall structure of 
OSM. In OSM-M1, the proline (P) was introduced to bend the loop back towards 
helix C and the alanine (A) served as a linker. OSM-WT*, OSM-M1 and OSM-M2 
were expressed at high levels in bacteria but not OSM-M3 suggesting that 
complete removal of the BC loop from OSM leads to instability in the overall 










Figure 3.10 Amino acid sequences of wild type OSM and the mutant variants of 
OSM with truncated BC loops 
Shown in gray are the α-helices present in the secondary structure of OSM as 
identified in the crystal structure (PDB: 1EVS). Each of the helices A, B, C and D 
are identified along with the BC loop region. Also highlighted in open box is the 







Figure 3.11 SDS-PAGE analysis of purified proteins 
8 μg of purified protein is loaded into each lane. 
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3.2.2.2. Structural characterization of OSM-M1 and OSM-M2 
 
Minor alterations in the size and composition of BC loop could potentially induce 
a global change in the overall structure of OSM. To determine whether the 
modified proteins (OSM-M1 and OSM-M2) still retained native alpha helical 
content we analyzed the recombinant proteins using circular dichroism (CD).  
Figure 3.12 shows the molar ellipticity [θ] plotted against the wavelength for LIF, 
OSM-WT*, OSM-M1 and OSM-M2. All molecules displayed similar absorption 
behavior. Analysis using the software programs SELCON3, CONTINLL and 
CDSSTR revealed that both LIF and OSM-WT* have approximately 60% alpha 
helical content with the remaining primarily being loop regions. This is in good 
agreement with the crystal structures available for LIF and OSM. Analysis also 
showed that both OSM-M1 and OSM-M2 have similar 60% alpha helical content 
with the remaining being loop regions. These results suggest that shortening the 
length of BC loop in OSM from 12 amino acids to 7 or 4 amino acids did not 







Figure 3.12 Modifications in the BC loop area of OSM did not induce a global 
change in the protein’s structure. 
A) Average of 3 CD spectra of the purified proteins plotted as molar ellipticity (θ) 
versus the wavelength. B) Theoretical estimation of the secondary structural 
content for each protein using SELCON3, CDSSTR and CONTINNL. Values are 
presented as mean of estimations given by the three programs ± SD. 
 
 126
3.2.2.3. Functional Evaluation of wild-type* and mutant OSMs in their 
activation of OSMR:gp130 complexes 
 
To determine whether the BC loop on hOSM is required for OSMR binding, we 
stimulated A375 melanoma cells with the wild type and mutant forms of OSM. 
A375 melanoma cells express OSMR and gp130 on their cell surface but not 
LIFR (50).  To confirm the absence of LIFR, A375 melanoma cells were treated 
with increasing doses of LIF and OSM-WT*. In agreement with previous 
observations, these cells did not respond to LIF but responded to OSM-WT* in a 
linear, dose dependent manner as demonstrated by activation of STAT3 (Figure 
3.13A). In addition, pretreatment of A375 melanoma cells with LIFR specific 
antagonist, LIF05, showed no effect on hOSM-WT* activity while pretreatment 
with anti-gp130 antibody completely abolished hOSM-WT* activity (Figure 
3.13B). These results again confirm that hOSM-WT* utilizes OSMR:gp130, but 
not LIFR:gp130 to activate STAT3 in A375 melanoma cells. When treated with 
OSM-M1 and OSM-M2 which have truncated BC loops, to our surprise, the A375 
cells exhibited a 3 – 4 fold increase in their STAT3 activation relative to OSM-
WT* (Figure 3.14). The mutant molecules however did not show any change in 
Erk 1/2 activation compared to OSM-WT*. Since OSM with truncated BC loops 
were able to activate OSMR:gp130 better than the wild-type* OSM (OSM-WT*), 
the BC loop is clearly not essential for OSM’s unique ability to bind OSMR but is 







Figure 3.13 Human Müller cells express LIFR, gp130 while A375 melanoma 
cells express OSMR, gp130 on their cell surface. 
A) Both LIF and OSM activate STAT3 in human retinal Müller cells in a dose 
dependent manner B) LIF05 (LIFR antagonist) is able to completely antagonize 
the STAT3 activation induced by both LIF and OSM suggesting that both LIF and 
OSM utilize LIFR:gp130 to activate STAT3 in Müller cells C) In A375 melanoma 
cells, only OSM is able to activate STAT3 in a dose dependent manner while LIF 
is not able to activate any STAT3 demonstrating that these cells express OSMR 






Figure 3.14 Activation of STAT3 and Erk 1/2 in A375 melanoma cells in 
response to different doses of wild type (OSM-WT) and the mutant forms of OSM 
(OSM-M1 and OSM-M2). 
Values are presented as mean ± SE. n ≥ 4. (*p<0.01, **p<0.001, compared to 
OSM-WT treatment at same dose). Contrary to our expectation, mutant OSMs 
with truncated BC loops (OSM-M1 and OSM-M2) exhibited 3-4 fold higher 
potency in activating STAT3 downstream OSMR:gp130. STAT3 activation in 
induced by LIF estimated by the representative data shown in figure 3.13C is 
shown for comparison. However, compared to the wild type, OSM-M1 and OSM-
M2 did not exhibit any difference in activating ERK1/2. 
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3.2.2.4. Functional Evaluation of wild-type and mutant OSMs in their 
activation of LIFR:gp130 complexes.  
 
To determine whether shortening the BC loop in OSM affected the ability of OSM 
to activate LIFR:gp130 receptors we used the recombinant proteins to stimulate 
human retinal Müller cell line. Müller cells respond to both LIF and OSM-WT* 
stimulation in a dose dependent manner by activating STAT3 (Figure 3.13C). To 
determine the receptor expression, the cells were pre-treated with recombinant 
LIF05 (a mutant LIF molecule that specifically antagonizes the activation of LIFR 
but not OSMR or gp130 (48,294)), before stimulating with LIF or OSM-WT*. At 
doses of 50 ng/ml, LIF05 was able to completely antagonize the STAT3 
activation induced both LIF and OSM-WT* demonstrating that the STAT3 
activation in Müller cells is dependent upon utilization of LIFR:gp130 and not 
OSMR:gp130 (Figure 3.13D). Treatment of Müller cells with wild-type* and 
mutant OSM molecules again show that OSM-M1 and OSM-M2 induce a 2 to 3 
fold greater activation of STAT3 compared to OSM-WT* at similar doses (Figure 
3.15). Also, OSM-M1 and OSM-M2 exhibited a similar 2 – 3 fold higher activation 
of Erk1/2 compared to wild type* OSM. Clearly, these data demonstrate that 
reducing the size of BC loop significantly improves OSM’s ability to bind and 




Figure 3.15 Activation of STAT3 and Erk 1/2 in human Müller cells in response 
to different doses of wild type (OSM-WT) and mutant forms of OSM (OSM-M1 
and OSM-M2) 
Values are presented as mean ± SE. n ≥ 4. (*p<0.05, **p<0.01, compared to 
OSM-WT treatment at same dose). As seen in A375 melanoma cells, mutant 
OSMs with truncated BC loops (OSM-M1 and OSM-M2) exhibited higher potency 
in activating STAT3 downstream OSMR:gp130. STAT3 activation induced by LIF 
estimated by the representative data shown in figure 3.13A is shown for 
comparison. Unlike in A375 melanoma cells, OSM-M1 and OSM-M2 exhibit 2-3 
fold higher activation of ERK1/2 in Müller cells. 
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3.2.2.5. Removal of BC loop does not alter the requirement of core FXXK 
motif in active site III.  
 
Given its proximity to the site III, it is possible that removal of the BC loop created 
an alternative site III that could facilitate a stronger binding to LIFR and OSMR. In 
order to determine whether the mutant OSMs, OSM-M1 and OSM-M2 still utilize 
the FXXK motif to interact with LIFR or OSMR, we mutated both F160 and K163 
to alanines (A) and evaluated their activity on Müller cells and A375 cells. Müller 
cells were serum starved for 30 minutes before stimulation with 1 ng/ml 
concentration of either the wild type (FXXK) or the alanine mutant versions 
(AXXA) of OSM-WT*, OSM-M1 and OSM-M2 (Figure 3.16). As expected, 
mutating FXXK to AXXA in OSM-WT* completely abolishes its activity on both 
A375 melanoma and Müller cells. In a similar manner, both OSM-M1 and OSM-
M2 showed complete loss of activity upon alanine substitution at the active site 
III.  This suggests that the mutant OSMs with shorter BC loop still utilize the 





Figure 3.16 OSM with truncated BC loop still utilizes the FXXK motif to activate 
LIFR and OSMR. 
A375 melanoma and Müller cells are stimulated with 1 ng/ml doses of various 
forms of OSM containing either the wild type (FXXK) or alanine substituted 
(AXXA) active site III. As expected, alanine substitution in wild-type OSM leads to 
complete abolition of its activity on both A375 melanoma and Müller cells. In a 
similar way, both OSM-M1 and OSM-M2 showed complete loss of activity upon 








3.2.2.6. Reducing the size of BC loop improves OSM’s affinity towards LIFR 
and OSMR 
 
The ability of OSM-M1 and -M2 to activate receptor signaling at lower 
concentrations implied that these proteins have higher affinity towards LIFR and 
OSMR. To directly measure the binding kinetics of these ligand-receptor 
interactions, we used surface plasmon resonance (SPR).  The cytokines (LIF, 
OSM-WT*, OSM-M1 and OSM-M2) were immobilized on the sensor chip surface 
while recombinant soluble receptors were used as the analytes (Figure 3.17). 
The analysis revealed that LIF had a 23 fold higher affinity towards LIFR (KD = 
3.10 nM) than gp130 (KD = 72.38 nM) while OSM had a 2 fold higher affinity 
towards gp130 (KD = 22.69 nM) than LIFR (KD = 43.79 nM) (Table 3.2). This 
explains the sequential disparity between LIF and OSM in binding to LIFR and 
gp130 complexes. LIF, which exhibits a higher affinity towards LIFR would first 
bind LIFR and then bind to gp130 to form the stable trimeric complex. On the 
other hand, OSM which exhibits a higher affinity towards gp130, would first bind 
to it and then binds LIFR to form the trimeric complex. When the size of BC loop 
is reduced from 12 aa to 7 aa (OSM-M1) the affinity of OSM towards LIFR 
improved dramatically (KD: 7.62 nM). When the size of BC loop is further reduced 
to 4 aa the affinity improved even more (KD: 2.74 nM). However, changing the 
size of BC loop did not affect OSM’s affinity towards gp130 significantly (KD: 
OSM-WT* = 22.69 nM, OSM-M1 = 26.26 nM and OSM-M2 = 21.49 nM) (Table 
 134
3.2). OSM-M1 and -M2 proteins with shorter BC loops clearly display a higher 
affinity for LIFR still retaining their relatively high affinity towards gp130.  
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Figure 3.17 Kinetic analysis of LIFR and gp130 interaction towards LIF, OSM-
WT, OSM-M1 or OSM-M2. 
Soluble LIFR (left panel) or soluble gp130 (right panel) at various concentrations 
were injected over an SPR sensor chip with immobilized ligand (LIF, OSM-WT, 
OSM-M1 or OSM-M2) at flow rates of 25 μl/min. Responses obtained were 
corrected for background signal using a control flow cell. Association and 
dissociation rates are derived by global analysis of the response curves fit to a 
1:1 kinetic model using QDat software (BioLogic Software, Ltd. Knoxville TN and 
Nomadics, Inc. Stillwater, OK) using 1:1 stoichiometry. Models are indicated in 
smooth gray line overlaid over response curve traces. [Experiments were 
performed with assistance from ICX Technologies, Oklahoma City, OK] 
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Table 3.2 Comparison of association (ka), dissociation (kd) and equilibrium 
dissociation (KD) constants for LIFR and gp130 binding to LIF, OSM-WT, OSM-






Together, these results suggest that the BC loop on OSM is presenting a steric 
hindrance for OSM’s direct interaction with LIFR. Also, reducing its size not only 
enhances its affinity towards the receptor but also its ability to form a stable 
complex with cell surface receptors as demonstrated by the improved STAT3 
activation. 
 
Similar binding studies with OSMR showed that neither the wild-type* nor the 
mutant OSMs (OSM-M1 and OSM-M2) exhibit a direct interaction with OSMR 
(Figure 3.18). This is in agreement with previous results which reported a lack of 
direct interaction between OSM and OSMR in the absence of gp130 (4). In order 
to evaluate the binding kinetics of OSMR towards gp130 bound wild-type* or 
mutant OSMs, we have immobilized soluble gp130 on the sensor chip surface 
and treated with human OSM followed by OSMR. However, accurate association 
and dissociation constants could not be determined for these interactions since 
there was a progressive loss in the binding capacity of gp130 with each round of 
binding and regeneration. To overcome this issue, we used ELISA and 
performed similar binding assays where gp130 immobilized on the ELISA plate 
was sequentially treated with saturating amounts of wild-type* or mutant OSMs 
followed by increasing concentrations of soluble OSMR. Results show that after 
binding to gp130, both the wild type and the mutant OSMs start exhibiting a 
strong affinity towards OSMR (Figure 3.19B; Table 3.3). However, when tested 
for direct interaction, again, none of these cytokines displayed detectable 
affinities towards OSMR (Figure 3.19A; Table 3.3). This suggests that prior 
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bidning to gp130 is required for OSM to start displaying detectable affinities 
OSMR (Figure 3.19, Panel A vs. B). Again, as observed towards LIFR, there is a 
significant improvement in OSM’s affinity towards OSMR when the BC loop is 
truncated (KD,App: OSM-WT* – 10.86±1.7 nM; OSM-M1 – 3.71±0.67 nM; OSM-M2 
– 2.19±0.28 nM). This represents a 3 – 4 fold increase in the affinity towards 
OSMR upon BC loop truncation on OSM. These results again confirm that the 
BC loop on OSM presents a steric hindrance for both LIFR and OSMR 
interaction towards OSM and its truncation results in significant improvement in 
both the affinity towards the receptors and also the biological activity. 
 
The gp130 induced co-operativity for OSM binding towards OSMR prompted us 
to check if a similar co-operativity is induced towards LIFR binding. However, our 
results revealed that prior gp130 binding to OSM or LIF did not affect their 
affinities towards LIFR significantly (Figure 3.19, Table 3.3). This suggests that, 
unlike in the case of OSMR, LIFR and gp130 bind to the cytokines in a non-
cooperative manner. Again, as observed in SPR, the mutant OSMs with 
truncated BC loop exhibited a stronger affinity towards LIFR compared to the 
wild-type* (Figure 3.19C and 3.19D, Table 3.3). However, to be noticed is the 
fact that the equilibrium dissociation constants obtained for LIFR binding using 
ELISA were significantly higher than the values obtained using SPR. This could 
be the result of structural distortions involved ELISA immobilization and also the 
indirect method of bidning analysis which involves series of washing and 




Figure 3.18 Neither wild type (OSM-WT) nor the mutant forms of OSM with 
truncated BC loop (OSM-M1 and OSM-M2) exhibit a direct affinity towards 
OSMR. 
Soluble OSMR at various concentrations were injected over an SPR sensor chip 
with immobilized ligands (LIF, OSM-WT, OSM-M1 or OSM-M2) at flow rates of 
25 μl/min. Responses obtained were corrected for background signal using a 
control flow cell. Association and dissociation rates are derived by global analysis 
of the response curves fit to a 1:1 kinetic model using QDat software (BioLogic 
Software, Ltd. Knoxville TN and Nomadics, Inc. Stillwater, OK) using 1:1 





Figure 3.19 ELISA analysis of OSMR and LIFR binding towards LIF, OSM-WT*, 
OSM-M1 and OSM-M2 or gp130 bound LIF (gp130:LIF), OSM-WT* 
(gp130:OSM-WT*), OSM-M1 (gp130:OSM-M1) and OSM-M2 (gp130:OSM-M2).  
Cytokines (LIF, OSM-WT*, OSM-M1 or OSM-M2) immobilized on ELISA plate in 
the absence (A,C) or presence (B,D) of gp130 were treated with various 
concentrations of soluble OSMR  (A,B) or soluble LIFR (C,D). Equilibrium KD 
values were estimated using a non-linear curve fitting to the binding data using 
GraphPad Prism (Graph Pad Software. LaJolla, CA) (See Table 3.3) 
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Table 3.3 Comparison of apparent equilibrium dissociation constant (KD,App) 
values (nM) for direct interaction of LIFR and OSMR with LIF, OSM-WT*, OSM-
M1 and OSM-M2  or the interaction of LIFR and OSMR with gp130 bound LIF, 






3.2.2.7. Inhibition of A375 melanoma cell proliferation 
 
OSM was initially discovered by its ability to suppress proliferation of several 
melanoma cell lines including A375 melanoma cells (1). To test whether the 
improvement in OSM’s affinity towards OSMR with truncation of BC loop has any 
functional consequence we monitored the growth of A375 melanoma cells in the 
presence or absence of wild-type* and mutant OSMs. As expected, treating A375 
cells with wild-type* OSM inhibited their proliferation in a dose dependent manner 
(Figure 3.20). At concentrations of 20 ng/ml, OSM-WT* was able to suppress 
A375 melanoma cell proliferation by ~40% while a concentration of 50 ng/ml was 
able to suppress the proliferation by ~80%. In contrast, both OSM-M1 and OSM-
M2 were both able to suppress the proliferation of A375 melanoma cells at 
significantly lower concentrations. While 10 ng/ml concentrations were enough 
for the mutant OSM molecules to inhibit the proliferation by ~60%, 20 ng/ml 
concentrations suppressed their proliferation by ~80%. These data clearly 
suggest that reducing the size of BC loop improves the ability of OSM to activate 




Figure 3.20 A375 melanoma cell proliferation in the presence or absence of   
OSM-WT, OSM-M1 and OSM-M2. 
OSM inhibited the proliferation of A375 melanoma cells in a dose dependent 
manner with 50 ng/ml being able to exhibit a near complete suppression. 
However, at similar dosages, OSM-M1 and OSM-M2 were more potent in 
suppressing the proliferation of A375 melanoma cells. Average of cell numbers 
on 4th and 5th day of proliferation are normalized against the control cells and 





3.2.2.8. Protection of retinal photoreceptors 
 
As described in chapter 3.1, IL-6 family cytokines are strongly implicated in 
neuroprotection. Previous studies by LaVail et al., (146,301) and Ueki et 
al., (149) have shown that IL-6 family cytokines rescue photoreceptors 
from damaging effects of constant light and retinal degenrations induced 
by inherited genetic mutations. To test whether the mutant OSM’s (OSM-
M1 and OSM-M2) which display improved ability in binding and activating 
LIFR:gp130 and OSMR:gp130 complexes exhibit an enhanced ability in 
protecting the retinal photoreceptors compared to wild-type* OSM we 
injected 0.25 μg of OSM-WT*, OSM-M1 or OSM-M2 in a total volume of 1 
μl in the left eye of Balb/cJ mice while the right eye, injected with PBS, 
served as control. 2 days following intravitreal injection, the mice were 
exposed to damaging light (4000 lux) for 4 hours. Following a 4 day 
recovery period after the light damage, eyes were enucleated and 
processed for histological analysis. Photoreceptor cell death in each group 
was assessed my morphometric analysis. Representative sections for 
each treatment is shown in figure 3.21A while quantitative analysis of the 
number of photoreceptors in each group are shown in figure 3.21B. 
Exposure to 4000 lux for 4 hours caused significant damage to retinal 
photoreceptors injected with PBS. Compared to normal eyes, which 
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contain ~12 rows of photoreceptor nuclei in their outer nuclear layer (ONL), 
PBS injected eyes retained only 3-4 nuclei layers in the ONL. While OSM-
WT* did not show significant protection of photoreceptors, OSM-M1 and 
OSM-M2 were clearly more potent and lead to retainment of 6-7 
photoreceptor nuclei layers after the light damage. Again, this clearly 
suggests that the improved affinity of OSM towards OSMR and LIFR by 




Figure 3.21 Mutant OSM’s with truncated BC loop (OSM-M1 and OSM-M2) are 
more potent than the wild-type* OSM (OSM-WT) in protecting the photoreceptor 
cells from light damage (LD). 
A) Representative sections and B) quantification of number of rows of 
photoreceptor nuclei in the outer nuclear layer (ONL) along the vertical meridian 
of the retinas treated with PBS (□), OSM-WT* (●), OSM-M1 (♦) or OSM-M2 (▲) 
and subjected to light damage (4000 lux for 4 hours). Quantification of 
photoreceptor nuclei layers from a normal retina (■) is shown for comparison. n = 
3; value = mean  SD (*p<0.05, vs. LD eyes, paired t-test). ONL – outer nuclear 




IL-6 family cytokines are pleitropic cytokines that elicit a wide variety of 
responses in vivo mediated by the activation of signal transducing receptors 
gp130, LIFR and OSMR. Among these cytokines, OSM is unique in terms of its 
ability to signal through two different receptor complexes, LIFR:gp130 (type I) 
and OSMR:gp130 (type II). Also, OSM is unique in the order in which it binds to 
its receptors i.e. gp130 followed by LIFR or OSMR (5,21,25,324). Based on the 
crystal structures and mutational analysis conducted, it has been proposed that 
the ability of OSM to interact with OSMR must result from the involvement of 
additional residues in the vicinity of its “FXXK” motif which is required for OSM’s 
binding to LIFR and OSMR (4). In comparison to other IL-6 family cytokines, we 
have identified that OSM has a unique α-helical loop between its B and C 
helices. This BC loop lies in close proximity to site III which contains the core 
“FXXK” motif. The size and location of this loop suggested that it is possibly 
playing an essential role in OSM’s unique ability to bind OSMR. However, 
contrary to our expectation, shortening this loop resulted in proteins that display 
higher affinity towards OSMR as indicated by improved activation of signal 
transduction and inhibition of A375 melanoma cell proliferation. Additional studies 
using Müller cells showed that the truncation of BC loop on OSM improves its 
ability to activate LIFR:gp130 complexes also. These observations suggest that 
while the alpha helix in BC loop of OSM is not responsible for binding to OSMR, 
its primary role seems to be to modulate the function of OSM.  
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It has been reported that LIF has a strong preference for binding LIFR prior to 
binding gp130 while OSM has a preference for binding gp130 prior to binding 
LIFR (21,23,48). Affinity measurements by SPR suggest that the mechanism 
behind the unique ability of OSM to first bind gp130 can be explained by its 
relative affinity to each receptor subunit. OSM has a two fold higher affinity for 
gp130 than for LIFR. LIF, which lacks the BC loop, has a 23 fold higher affinity 
for LIFR than for gp130. When the BC loop on OSM is truncated, OSM starts 
displaying a higher affinity towards LIFR than towards gp130. Clearly, the 
reduced affinity of OSM towards LIFR is caused by the BC loop and is likely 
playing a role in the difference in sequential binding between LIF and OSM.  
 
The inability of OSM to bind soluble OSMR directly is consistent with previous 
observations (4). Like IL-6 and CNTF which require binding to their alpha 
receptor before they can bind to their signal transducing receptors, these results 
suggest that OSM requires binding to gp130 before it can bind OSMR. To test 
this, we conducted OSMR binding analysis for these cytokines in the presence of 
gp130. Results showed that gp130 binding induces remarkable co-operativity 
towards OSMR binding in both the wild type and mutant OSMs (OSM-WT*, 
OSM-M1 and OSM-M2) i.e. the cytokines by themselves do not exhibit any direct 
interaction with OSMR, but upon prior binding to gp130 they start exhibiting a 
strong affinity towards OSMR. While the data clearly showed that OSM utilizes 
the ‘FXXK’ motif for OSMR binding, binding to gp130 might expose otherwise 
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hidden residues on OSM required for OSMR binding or alter the OSM structure 
to move hindering residues away from the binding interface leading to the strong 
binding. Solving the structure of OSM in complex with gp130 would prove 
valuable in identifying these changes.  
 
Finally, a number of studies conducted over the last decade have revealed the 
diverse biological roles of OSM. One among them is the growth modulation of 
cells which include tumor cells, epithelial cells, fibroblasts and plasmacytoma 
cells (1,170,171,174,326,327). In agreement with earlier studies, our results 
show that OSM inhibits the growth of A375 melanoma cells in a dose dependent 
manner (Figure 3.15). Mutant OSM proteins with a shorter BC loop exhibit 
increased potency in suppressing their proliferation (Figure 3.15). This 
improvement in OSM’s function could prove valuable in treating diseases 
associated with melanoma. Previous research in our lab has shown that STAT3 
activation induced by IL-6 family cytokines is neuroprotective and prevents 
photoreceptor cell death under oxidative stress (149,328). Our experiments show 
that the mutant OSM molecules, OSM-M1 and OSM-M2 are more potent than 
the native cytokine (OSM-WT*) in protecting the photoreceptor cells from 
oxidative damage. These molecules could thus serve as potent therapeutic 
agents in preventing photoreceptor degeneration induced by inherited genetic 
mutations such as retinitis pigmentosa. Also, OSM plays a key role in the 
inflammatory response to injury and infection. OSM secreted from activated T 
cells and monocytes stimulates expression of 1) acute phase proteins (APPs) in 
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the liver  (87) 2) P-selectin and E-selectin on endothelial cells and (97,98) 3) 
TIMP-1 in fibroblasts (105,329) all of which promote wound repair. The mutant 
OSM proteins could thus potentially find therapeutic application in promoting 
wound healing also. 
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3.3. Sustained Delivery of human Oncostatin M (hOSM) to 




Diseases of the posterior eye segment pose a major challenge in ophthalmology. 
Several of these diseases, such as age related macular degeneration (AMD), 
retinitis pigmentosa (RP), glaucoma and diabetic retinopathy, necessitate long-
term treatment with appropriate drugs. However, delivering drugs to the posterior 
eye has been a problem for decades because of various physiological and 
anatomical barriers. As summarized by Geroski and Edelhauser (330), there are 
four major routes for delivering drugs to the posterior segment: systemic, topical, 
intravitreal and transscleral. The systemic route has the obvious advantage of 
easy administration, but is largely ineffective because of the relatively small 
volume of vasculature present in the eye and also the resistance imposed by 
blood-retinal barriers (331). Topical delivery is very effective for delivering drugs 
to anterior segment. However losses to the tear film, convection of the drug by 
circulating aqueous humor (which flows posterior-to-anterior, away from target 
area) and the long distance to the retina combine to reduce the efficiency of 
topical delivery to a level only slightly above that of systemic delivery (332). 
Intravitreal injection of drugs has proven very effective and has been the method 
of choice for a long time since it offers the advantage of delivering the drug near 
target tissue and eliminates the necessity to cross retinal barriers. This mode of 
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delivery has gained popularity since the advent of new antibody based 
treatments for age-related macular degeneration (AMD) (eg. Avastin®, 
Lucentis®). However, many drugs that are used to treat vitreoretinal diseases 
have a narrow concentration range within which they are effective (333). Higher 
concentrations can be toxic, and lower concentrations can be insufficient to treat 
the disease. Hence, it is critical to maintain desired concentrations of drug inside 
the eye and this mandates frequent injection of drugs. Unfortunately, this 
increases the risk of infection and also poses the threat of serious side effects 
like vitreous hemorrhage and retinal detachment (334). Therefore other less 
invasive and long acting treatment modes are needed. Recent studies have 
shown that transscleral delivery of drugs can provide the localization of drugs 
similar to intravitreal injection and also offer safety levels comparable to topical 
administration if a constant release vehicle is employed (272,335-339). The 
sclera has a large surface area and is highly diffusible to drugs below molecular 
weight of 70kDa, making it an appealing route for delivery of small drugs to the 
posterior eye (335,340-342). Figure 3.22 shows a simplified anatomy of the 





Figure 3.22 Schematic representation of the eye. 
Shown in the inset is the representation of various barriers along the route for 
transscleral drug delivery. 





Since the pioneering work of Wichterle in the 1960s (215-217) hydrogels have 
generated great interest among scientists as potential vehicles that can deliver 
drugs in a controlled, pre-dictated manner. Hydrogels offer a number of 
advantages over traditional methods; they trigger minimal immune response 
when implanted, can hold large amounts of drug, prevent their rapid clearance 
and release drugs in a sustained manner over long periods of time (343). A 
number of polymers have been studied for creating transscleral drug delivery 
implants. Examples include polyvinyl alcohol (PVA), ethylene vinyl acetate 
(EVA), poly(ethylene glycol) (PEG), poly(lactic acid) (PLA), poly(glycolic acid) 
(PGA), their co-polymer, poly(lactic-co-glycolic acid) (PLGA) 
(272,291,335,336,338,339,344-347).  
 
Previous work and our results have shown that STAT3 activation induced by IL-6 
family cytokines protect the photoreceptor cells in the retina from oxidative stress 
induced by bright light and inherited genetic mutations (149,150,328). However, 
we have also shown that when delivered in large doses, these cytokines can 
induce photostasis leading to transient loss of visual function (149). Thus, a 
judicious release of these drugs in a controlled manner is essential for these 
molecules to be used in therapy for treatments. Since these molecules are small 
(M.W ~20kDa), controlled delivery via the transscleral route using hydrogel 
implants proves to be an effective way to get these drugs to the photoreceptors. 
We have used functionalized PEG monomers to create hydrogel matrices 
encapsulated with human oncostatin M (hOSM) and release studies in vitro have 
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shown that the macromer concentration can be varied effectively to tailor the 
release rates of the drug from these matrices. When implanted sub-conjunctivally 
in a mouse eye, the PEG hydrogel released hOSM in a controlled manner 
leading to sustained activation of STAT3 as predicted by in vitro and 




3.3.2.1. Estimation of volumetric swelling ratio (Q), mesh size (ξ) and 
diffusivity of the drugs in hydrogel (Dg) 
 
Hydrogels with varying amounts of PEG 5000 macromer (10%, 20%, 30% 40% 
and 50% by weight) were made for this analysis. Immediately after photo-
polymerization, the hydrogels were each weighed and placed in a reservoir of 
continuously agitated PBS solution. At regular time intervals, the hydrogels were 
taken out of the swelling medium and weighed. This process was continued until 
the gel stopped swelling as indicated by a constant final weight. The weight of gel 
at this equilibrium swelling point was noted as (Meq). Results indicated that by 2 
hours of incubation, gels of all compositions reached a steady-state equilibrium 
swelling. The gels were then dried under vacuum for 2 days to obtain the dry 
weight of the hydrogels (Md). Equilibrium mass swelling ratio of the hydrogels 
was obtained by dividing the weight of hydrogel at equilibrium swelling point (Meq) 





  )(Q Ratio Swelling Mass =  
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Results show that the mass swelling ratio of the PEG hydrogels showed an 
inversely proportionate correlation with the weight percent of the macromer in the 
hydrogel. While 10% hydrogel has an equilibrium mass swelling ratio (Qm) of 
11.9 ± 0.15, 20%, 30%, 40% and 50% hydrogels displayed an equilibrium mass 
swelling ratio (Qm) of 7.1 ± 0.09, 5.3 ± 0.02, 3.9 ± 0.04 and 2.5 ± 0.12 
respectively (Figure 3.23A).  
 
These values of mass swelling ratios are then used to determine the volumetric 
swelling ratio (Q) and the polymer mesh size (ξ), using the scaling laws 
developed by Peppas and co-workers (250,348). 
( )
2




Where, υ1 is the specific volume of PBS and υ2 is the specific volume of PEG. 
Using the volumetric swelling ratio, one can estimate the mesh size of the 
hydrogel network using the equation: 
o
1/3 rms Q=ξ  
Where, rmso is the root mean squared end-to-end distance of the PEG 
macromer. This can be estimated using the equation: 
( ) ( ) 2/12/1navgo n C l  rms =  
Where, lavg is the average bond length of the PEG macromer, Cn is the 




Estimation of volumetric swelling ratios revealed a similar inverse correlation with 
weight percentage of the macromer in the hydrogel. Volumetric swelling ratio (Q) 
of 10%, 20%, 30%, 40% and 50% gels were 13.0 ± 0.16, 7.7 ± 0.10, 5.7 ± 0.03, 
4.2 ± 0.04 and 2.7 ± 0.14 respectively (Figure 3.23B). In agreement with the 
above two values, estimation of mesh size of the hydrogel revealed that as the 
amount of macromer content in the hydrogel increased, there is a corresponding 
decrease in mesh size of the hydrogel network. Mesh sizes (ξ) of 10%, 20%, 
30%, 40% and 50% gels were 12.9 ± 0.05 x 10-7 cm, 10.8 ± 0.05 x 10-7 cm, 9.8 ± 
0.01 x 10-7 cm, 8.9 ± 0.03 x 10-7 cm and 7.9 ± 0.13 x 10-7 cm respectively (Figure 
3.23B). These results clearly suggest that the macromer content inside a 
hydrogel can be varied to effectively tailor the physical properties of the hydrogel.  
 
For a given drug molecule, one can easily estimate its diffusion coefficient inside 











r-1 D  D  
Where, Do is the diffusion coefficient of a drug molecule in aqueous solution, rs is 
hydrodynamic radius of the drug molecule. Do can be readily estimated using the 
‘Stokes-Einstein equation’ given below:  
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Where, kB -  Boltzmann’s constant ( = 1.38 x 10-16 cm2g/s2K), T – temperature in 
Kelvin, μ - viscosity of PBS and, the hydrodynamic radius of the drug molecule 
(rs) can be estimated using the equation: 
3/1
A
s N   4









Where, MW – molecular weight of the drug molecule, ρ - density of PBS, NA – 
Avogadro’s number (= 6.023 x 1023). 
 
However, it must be understood that these predictions for Dg, Do and rs assume 
that the drug molecule is spherical, while in reality the proteins exist in a wide 
range of shapes often deviating from the spherical shape. The molecule 
employed for our studies here, hOSM, exists in a conformation more closer to the 
cylindrical shape. Thus, empirical observations for the drug release rates could 
show significant deviation from the theoretical predictions particularly, when the 
theoretically predicted mesh sizes are closer to drug radius. 
 
As expected, theoretical predictions revealed that as the macromer content 
inside the hydrogel increased, the diffusivity of hOSM decreased in a 
proportionate manner (Figure 3.24). This is expected since increasing the 
macromer content decreases the mesh size of the hydrogel leading to a 





Figure 3.23 Changes in mass swelling ratio, volumetric swelling ratio and mesh 
size of PEG hydrogels as a function of macromer content 
A) Changes in mass swelling ratio (Qm) of PEG hydrogels with various amounts 
of macromer (10%, 205, 30%, 40% and 50% by weight) as a function of time. All 
hydrogels reached an equilibrium within first 40 mins and remained stable later. 
B) Changes in volumetric swelling ratio (Q) and mesh size (ξ) as a function of 
macromer content in the hydrogel. As expected, both the swelling ratio and mesh 






Figure 3.24 Changes in diffusivity (Dg) of hOSM through PEG 5000 DA 




3.3.2.2. Theoretical Estimation of Drug Diffusion from Hydrogels 
 
As described in the materials and methods section, the rate of drug diffusion from 
the polymeric hydrogels can be estimated by solving the Fick’s law of diffusion 
equation. Since we are synthesizing hydrogels of high aspect ratio, a valid 
assumption of unsteady-state ‘one-dimensional’ diffusion from either face of the 
gel can be made. 
 
3.3.2.2.1 Concentration profile in drug loaded hydrogel 
 
Fick’s Law: 










∂                                         Eqn 1 
Where, C is the concentration of drug inside the gel at time t and position x, and 
Dg is the diffusion coefficient of the drug inside swollen hydrogel. The hydrogel is 
non-degradable and thus the structural properties of the hydrogel and thus 
diffusion coefficient of the drug will stay constant throughout the release process.  
 
Boundary Conditions: 
BC 1        ( ) 0, =± tLC
BC2                            ( ) oCxC =0, LxL +<<−  









Using the boundary conditions listed above, Crank (349) has derived the 
equation for estimating concentration profile with respect to time and position 












































Based on the diffusivity (Dg) values obtained earlier (figure 3.24), we have solved 
for changes in the concentration profile of hOSM in 10% and 50% PEG 5000 
diacrylate hydrogels. Shown in figure 3.25 is the comparison of changes in 
concentration profiles with respect to time and position in a 10% and 50% PEG 
hydrogel. As expected, the concentration of hOSM in both hydrogels decreases 





Figure 3.25 Theoretical predictions for changes in the concentration profile of 
hOSM through a hydrogel slab as a function of time. 
An initial loading of hOSM at a concentration of 10μg/ml is assumed. Diffusion is 
one-dimensional and symmetrical about the central plane as described in the 





3.3.2.2.2 Fractional Release of the Drug 
 
Release of the drug from a hydrogel is normally represented in terms of fractional 
release with respect to time. To obtain this, one can integrate the concentration 
‘C(x,t)’ with respect to ‘x’ and obtain the mass of the drug inside the hydrogel and 
thus the mass of drug released from the hydrogel as function of time.  
 
Mass retained in the one-dimensional plane at time (t) = 0 is  LCo 2⋅






Mass retained at time (t) = ∞ is 0  
 






−= ),(2  
Total mass of the drug that can be released ( ) is M(in pellet at t = 0)  ∞M
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Solving for the integral on the numerator, we can get (See Appendix A2 for 




































Using this equation, we have solved for the fractional release of hOSM from 10% 
and 50% PEG 5000 hydrogels.  
 
Shown in figure 3.26A is a comparison of the release profiles from these two 
hydrogels. Again, as expected, the release of hOSM from 10% hydrogel was 
significantly faster than that from 50% gel at earlier time points (Figure 3.26B). 
These results predict that for 10% gel, ~50% of the drug comes out within the 
first 2 days. While the next 45% of the drug takes about 10 days to come out of 
the hydrogel. Clearly, as the concentration gradient between the hydrogel and 
outside sink decreases with time, the release rate of the drug decreases and 
takes a longer duration to come out. In comparison, about 40% of the drug 
comes out of the 50% PEG 5000 hydrogel in the first 2 days. And, in the next 10 
days, another 50% of the drug comes out. When the release rates are compared, 
a similar trend of lowering release rate with time is observed for both gels (Figure 
3.26B). However, in the 50% gel, the decrease in release rates is not as rapid as 
in the 10% gel (Figure 3.26B). This can be attributed to the slow decrease in 
concentration gradient in 50% gel compared to 10% gel. Thus, at 12 days, the 




Figure 3.26 Theoretical predictions for fractional release (A) and average release 
rate (B) of hOSM through 10 wt% and 50 wt% PEG hydrogels. 
hOSM is relased out of both hydrogels in a time dependent manner, and as 
would be predicted, the drug comes out of 10% hydrogel at a faster rate than 
through the 50% hydrogel. The release rates of hOSM from both hydrogels 
decreases with time. However, the rate of decrease in the release rate is slower 
in the 50% hydrogel compared to 10% hydrogel (thin dotted line vs. thick solid 
line). 
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3.3.2.3. Drug Release Studies – In Vitro 
 
For empirical estimation of drug release from the PEG 5000 hydrogels, 100 μg of 
hOSM (MW: 23kDa, rs: 2.09x10-7 cm) encapsulated in 10 wt% and 50 wt% PEG 
hydrogels were synthesized as described in materials and methods. Immediately 
after polymerization, the hydrogels were weighed and placed in a 0.5 ml reservoir 
of PBS and maintained under continuous agitation. Agitation was carried out in a 
humidified environment to prevent evaporation of the aqueous solution. After 2 
days, 4 days, 8 days and 12 days of agitation, 10 μl samples were taken out of 
the reservoir solution and replaced with an equal amount of PBS to maintain the 
same volume. Samples taken out at different time points were subjected to BCA 
assay for determination of protein concentration. Percent release of OSM from 
the hydrogel was estimated using these values. As expected, results revealed 
that OSM diffused out of both the 10% and 50% hydrogels in a time dependent 
manner (Figure 3.27). In agreement with previous observations, hydrogel with 
higher macromer content (50% gel) showed a slow release of the drug in 
comparison to the hydrogel with a low macromer content (10% gel). In 10% gel, 
~95% of the drug diffused out by 12 days while in 50% gel, only 75% of the drug 
diffused out (Figure 3.27). When the drug encapsulated inside the hydrogel is 
changed to bovine serum albumin (BSA) which has a higher molecular weight 
and is bigger in size (MW: 69kDa, rs: 3.02x10-7 cm), the release rates were 
clearly slower than those for hOSM. While ~95% of hOSM diffused out of the 
10% gel by 12 days, only ~82% of BSA diffused out of a similar 10% PEG 
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hydrogel by the end of 12 days (compare figure 3.27 with 3.28). Again, while 
about 75% of hOSM diffused out of a 50% hydrogel by 12 days, only ~60% of 
BSA diffused out of a similar 50% hydrogel by the end of 12 days. Thus, both 








Figure 3.27 Percent release of hOSM from a 10% and 50% PEG hydrogel as a 
function of time. 
In good agreement with the model, hOSM is released out of the PEG hydrogels 
in a time dependent manner. And, the release rate from 10% hydrogel is faster 






Figure 3.28 Percent release of BSA from a 10% and 50% PEG hydrogel as a 
function of time. 
Again, in good agreement with the model, hOSM is released out of the PEG 
hydrogels in a time dependent manner. However, compared to the release of 





These empirical values for drug release from the hydrogel were in reasonably 
good agreement with the theoretically predicted values (Figures 3.27 and 3.28). 
However, there were two major deviations from the predictions. First, the 
empirically observed release rate was significantly higher during the first day in 
comparison to the model prediction. This could be because of sudden swelling of 
the hydrogel when placed in the reservoir, thus leading to a burst release of the 
drug. However, as shown earlier, the hydrogel stops swelling after the first two 
hours (Figure 3.23), thus preventing any further accelerated release thereafter. 
Second, in 50% gels, the final release of the drug by the end of 12 days found in 
these experiments was significantly lower than that predicted by the theoretical 
models. There are two factors that might potentially be playing a role here a) 
geometry of the protein and b) cross-reaction between the macromers and the 
proteins. Theoretical predictions for the release rates are based on the 
assumption that the drug molecules are spherical in shape (OSM radius: ~2.09 
x10-7 cm; BSA radius ~3.02 x10-7 cm). However, unlike BSA, which is closer to a 
spherical geometry, hOSM assumes a cylindrical geometry with a height of ~5.0 
x10-7 cm and a radius of ~1.0 x10-7 cm. In 10% gels, where the mesh size is 
~12.1 x10-7 cm, the drug sizes are relatively smaller and the shape does not 
affect the release rates significantly. However, in 50% gels where the mesh size 
is ~7.9 x10-7 cm, the shape of the drugs would play a significant role and lead to 
deviations from theoretical predictions. Secondly, the highly reactive free radicals 
generated by the acrylate groups during photopolymerization can cross-react 
with the free amines present in proteins, thus leading to their permanent 
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immobilization in the hydrogels. Again, this effect is more pronounced in the 50% 
gels because of the high abundance of macromers and the reactive acrylate 
groups.  
 
3.3.2.4. Drug Release Studies – In Vivo 
 
PEG hydrogels (10% and 50%) loaded with 10μg of hOSM were implanted sub-
conjunctivally at the posterior segment in Balb/cj mouse. The left eye was 
implanted with a blank gel to serve as a control. The mice were then placed back 
into their cages and maintained under normal cage room conditions. At desired 
time points, the mice were euthanized and the eyes were enucleated for Western 
blot analysis. In agreement with in vitro studies and release rate predictions 
(Figures 3.27 and 3.26B), Western blots show that there is a peak activation of 
STAT3 two days after the implantation followed by a decline in subsequent days 
(Figure 3.29). STAT3 activation sustained until 8 days post implantation and 
returned to basal levels by 12 days. The comparison between theoretical 
predictions and in vivo STAT3 activation pattern (Figure 3.30) also suggests that 
a release rate of at least 0.45 – 0.5 μg/day from the hydrogel is required to allow 
hOSM to overcome the clearance at choroid and RPE layers and induce STAT3 
activation inside the retina. A 50% gel made with the PEG 5000 did not show a 
significant difference in terms of STAT3 activation profile. Theoretical estimation 
of release rates from the hydrogel explains the reason for this observation. In 
spite of a slower release from the 50% gel, the release rates were still well below 
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the 0.45 – 0.5 μg/day release rate at the 12th day. Clearance at the choroid layer 
renders this release rate insufficient for hOSM to reach the retina and induce 
detectable levels of STAT3 activation. 
 
In agreement with the predictions, there is peak activation of STAT3 in the retina 
2 days after implantation followed by a steady decrease. The model suggests 
that a release rate of at least 0.5 μg/day is required for OSM to pass through the 




Figure 3.29 STAT3 activation profile in mouse retina after sub-conjunctival 
implantation with PEG hydrogels releasing hOSM. 
In agreement with in vitro studies and theoretical predictions, STAT3 showed 
peak activation 2 days after implantation followed by a steady decline until it 
reached basal levels by the end of 12 days. While mathematical equations 
predicted a slightly slower and longer release from 50% gel, in vivo STAT3 





Figure 3.30 Comparison of STAT3 activation in the retina with theoretical 




Most diseases in the posterior eye segment require treatment over long durations 
of time eg. AMD, retinitis pigmentosa, diabetic retinopahy. Owing to difficulties in 
delivery, intravitreal injection has been the method of choice for targeted delivery 
of therapeutic drugs to the posterior segment of the eye. However, repeated 
intravitreal injections often lead to serious complications such as vitreous 
hemorrhage, endophthalmitis and retinal detachment. On the other hand, one 
time delivery of large doses of drug can also lead to serious undesired side 
effects. Recently, transscleral drug delivery has been hypothesized to be an 
effective means for achieving therapeutic concentrations of drugs in the posterior 
part of the eye (330,335-337,339). It has been reported that scleral permeability 
is comparable to that of the corneal stroma (340,341). Similar to the corneal 
stroma route, the primary route for solute transport through sclera is by passive 
diffusion through an aqueous pathway.  
 
Results in chapter 3.1 have shown that STAT3 activation induced by IL-6 family 
cytokines protect the retina from oxidative injury induced by bright light. 
Sustained delivery of these molecules to retina would thus prove valuable in 
treating a number of blinding diseases like retinitis pigmentosa, which lead to 
photoreceptor cell death mediated by oxidative stress. To aid this attempt, we 
have designed PEG based hydrogels to release hOSM in a sustained, time-
dependent manner. Results have shown that the macromer content in hydrogels 
can be manipulated effectively to tailor the physical properties of the hydrogel. 
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Higher macromer content in a hydrogel leads to the fabrication of a more 
compact hydrogel network with smaller mesh sizes leading to low diffusivity of 
the drug molecule encapsulate inside the hydrogel. It takes about 12 days for 
95% of hOSM to come out of a 10 wt% PEG 5000 hydrogel, while a 50 wt% PEG 
5000 hydrogel allows only 75% of hOSM to diffuse out by the end of 12 days. 
When compared to theoretical model predictions, the empirical results showed 
good agreement in terms of drug release pattern from the PEG based hydrogels. 
However, empirical results showed the presence of a burst release of the drug 
initially. This can be attributed to the sudden swelling of the hydrogel when 
placed in PBS reservoir. Also, in gels made with 50% macromer, the release of 
the drug was significantly slower than that predicted by the models by the end of 
12 days. This is probably an effect of the cross-reaction between highly reactive 
acrylate groups with the free amines on hOSM and also its non-spherical 
geometry. 
 
When placed in vivo, hOSM released from the hydrogels induced STAT3 
activation in the retina in a time-dependent manner as predicted by the model. 
Results suggest that a release rate of at least 0.45 – 0.5 μg/day is required for 
the hOSM to cross the choroids, RPE barriers and reach the retina to induce 
STAT3 activation. Together these results suggest that the physical properties of 
PEG hydrogels can be effectively manipulated to obtain desired drug release 
rates and when implanted in the eye, these hydrogels successfully release 
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hOSM in a sustained time-dependent manner leading to STAT3 activation in the 
retina. 
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4. CONCLUSIONS AND RECOMMENDATIONS 
 
The current research has characterized the neuroprotective roles of IL-6 family 
cytokines in the context of retina followed by structural analysis of OSM and 
identifying its features that are responsible for its unique ability to display higher 
affinity towards gp130 rather than towards LIFR. As a result of this study, we 
have generated two mutant molecules of OSM that display higher potency in 
terms of activating the cell surface receptors and thereby executing the functions. 
In order to extend the therapeutic application of these molecules, we have 
characterized the utilization of PEG based hydrogels for controlled drug delivery.  
 
Previous work has shown that preconditioning with moderate oxidative stress 
(e.g. light-induced stress, mechanical stress or hypoxic stress) can protect retinal 
photoreceptor cells from a subsequent lethal dose of oxidative stress (151-
155,301,306). However, the mechanism for this inducible protection remained 
poorly understood. Based on previous studies (151,152), we have developed a 
preconditioning model by cyclically exposing the mice to stress inducing 
moderate bright light (600 lux) for 6 days (See figure 2.4 for model). Functional 
and morphological studies have revealed that this preconditioning shows 
remarkable protection of retinal photoreceptor cells from subsequent lethal dose 
of light stress (4000 lux for 4hrs). Real time RT-PCR analyses have shown that 
the neuroprotective cytokines belonging to IL-6 family are strongly up regulated 
in response to moderate oxidative stress. To check whether these cytokines are 
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playing a functional role in this preconditioning induced protection, we have 
exposed the retinal cells to LIFR inhibitor, LIF05, during preconditioning. 
Functional and morphological analyses following this inhibition showed a clear 
attenuation in the preconditioning-induced protection of the retinal 
photoreceptors. However, injection of LIF05 alone without preconditioning did not 
induce any photoreceptor cell death. This suggests that the activation of LIFR-
gp130 pathway mediated by IL-6 family cytokines plays an essential role in bright 
cyclic light preconditioning induced protection of retinal photoreceptor cells. In 
addition, the results also suggested that LIFR activation is not required for the 
normal function and survival of photoreceptors at physiological conditions. In 
agreement with the studies by Joly et al., (150) our results demonstrate that IL-6 
family cytokines endogenously upregulated in response to stress inside the retina 
are playing an essential role in protecting the photoreceptors from succumbing to 
oxidative stress. 
 
While the Müller glial cells are widely hypothesized to be the source of these 
cytokines (150) it is not yet clear how the stress signals sensed by the 
photoreceptors are transmitted to the Müller cells and induce them to express IL-
6 family cytokines. Joly et al., (150) and Rattner et al., (133) hypothesized that 
endothelin 2 (Edn2) secreted from photoreceptor cells in response to light stress 
stimulate Müller cells and induce them to express IL-6 family cytokines. However, 
it was again not clear whether the IL-6 family cytokines secreted from Müller cells 
directly act upon photoreceptor cells or induce an indirect signaling pathway via 
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activation of other cells in the retina that ultimately lead to protection of 
photoreceptor cells. Previous studies in our lab by Ueki et al., (149) have shown 
that IL-6 family cytokines can directly activate STAT3 in the photoreceptor cells 
(149). And, current studies in our lab show that the STAT3 activation, specifically 
in photoreceptor cells, is essential for the preconditioning induced protection. 
This suggests that, under stressed conditions, the IL-6 family cytokines secreted 
by Müller glial cells directly act upon the photoreceptor cells to trigger the 
activation of protective pathways which help the photoreceptors tolerate lethal 
stress and promote their survival (Figure 4.1). Future definitive studies on 1) 
identifying the molecules involved in transmitting the stress signals from 
photoreceptor cells to Müller glial cells and 2) identifying the molecular 
mechanism by which activated gp130 and STAT3 in photoreceptor cells leads to 
their survival would be very beneficial to the field. Studies identifying the target 
genes that are regulated by the activated transcription factor STAT3 in response 
to stress will provide clues for identifying the molecular mechanism involved in 
this induced protection. In addition, these results also suggest that designing 
potent agonists that can promote the actions of gp130 would prove very valuable 
in treating a number of blinding diseases like retinitis pigmentosa and age-related 






Figure 4.1 Schematic representation of hypothesized model for stress induced 
protection of photoreceptor cells. 
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Photoreceptor cells exposed to stress are hypothesized to release endothelin-2 
(Edn2) which acts upon Müller cells to induce expression of IL-6 family cytokines. 
These IL-6 family cytokines directly activate LIFR:gp130 on the surface of 
photoreceptor cells triggering activation of signaling pathways that lead to 
photoreceptor survival.  
 
In an attempt to design agonists for IL-6 family cytokines, we have closely 
studied the crystal structures of various IL-6 family cytokines. During this study 
we have identified a unique loop structure between the B and C helices of OSM 
which was not present on any other IL-6 family cytokine, including LIF which is 
closely related to OSM both in structure and function. Among IL-6 family 
cytokines, there has been an as yet unanswered question on how OSM, unlike 
other IL-6 family cytokines, can bind to a unique receptor called OSMR. 
Mutational analyses have revealed that OSM utilizes the same ‘FXXK’ motif, 
which is responsible for LIFR binding, to bind OSMR too (4). This has lead to a 
hypothesis that the difference in receptor specificity between hOSM and other 
LIFR activating cytokines is the result of structural differences between these 
ligands in the vicinity of the core ‘FXXK’ motif (4). Structural proximity to the 
‘FXXK’ motif and the orientation of the unique BC loop we have identified on 
OSM has lead us to hypothesize that the BC loop might be playing an important 
role in OSM’s unique ability to recognize OSMR. To test this, we have created 
mutant OSM proteins (OSM-M1 and OSM-M2) that have truncated BC loops. 
Surprisingly, OSMs with truncated BC loops (OSM-M1 and OSM-M2) displayed a 
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dramatic increase in potency in terms of activating the cell surface receptors 
OSMR: gp130. When tested for function on Müller cells that express LIFR and 
gp130, we found a similar behavior i.e. the mutant OSM molecules with truncated 
BC loops were more potent than the native cytokine. Re-analysis of OSM 
structure in comparison to LIF’s structure in complex with its receptors LIFR and 
gp130 suggested that the BC loop on OSM might be presenting a steric 
hindrance for LIFR’s interaction with OSM. In addition to the unique ability of 
OSM to bind OSMR, there is another abnormal behavior displayed by OSM i.e. 
unlike its other family members, OSM displays a high affinity towards gp130 than 
towards LIFR (21,23). Based on structural observations and the results we 
obtained, we hypothesized that the unique BC loop present on OSM is 
responsible for OSM’s lowered affinity towards LIFR. Kinetic and equilibrium 
binding studies using SPR and ELISA have revealed that OSM with truncated BC 
loops display dramatic increase in their affinity towards both LIFR and OSMR 
compared to native OSM. This suggests that the BC loop on OSM presents a 
steric hindrance for OSM’s interaction with LIFR. This is the first demonstration 
showing that a structural motif on OSM modulates its affinity towards LIFR by 
presenting a steric hindrance. The functional relevance of this lowered affinity 
towards LIFR is not known yet. However, during pregnancy there is a robust 
increase in the concentrations of soluble LIFR (sLIFR) in circulation (350) and 
this sLIFR negatively influences LIF levels by competitively binding the free LIF 
thus preventing it from activating membrane bound LIFR on cells. However, like 
LIF, if OSM were to exhibit a strong affinity towards LIFR it would also be 
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scavenged out of circulation severely compromising its ability to promote wound 
healing during period of pregnancy. In vivo studies investigating the role of BC 
loop in this context would be beneficial in assigning a functional role for the BC 
loop on OSM.  
 
While conducting the binding experiments, we were however not able to detect 
any direct affinity for either OSM or its mutants towards OSMR. Similar 
observation has been reported for OSM earlier (4). However, in the presence of 
gp130, these molecules showed a strong affinity towards OSMR. This suggests 
that binding to gp130 might expose otherwise hidden residues on OSM required 
for OSMR binding or alter the OSM structure to move hindering residues away 
from the binding interface. Structural studies of OSM in complex with gp130 
would be useful in characterizing the structural changes induced in OSM by 
gp130 binding. Similar affinity conversion was not observed towards LIFR. This 
suggests that unlike OSMR, LIFR and gp130 participate in a non-coopertaive 
binding to form the signaling complex with the cytokines. 
 
Also, during this study we have demonstrated that the increase in potency of 
OSM by truncating its BC loop is functional; compared to the native OSM, both 
OSM-M1 and OSM-M2 display significantly higher ability in suppressing the 
proliferation of A375 melanoma cells. This increased potency in suppressing the 
melanoma cells would prove very valuable in treating cancer patients. However, 
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in vivo studies optimizing the dose ranges are needed to demonstrate the 
applicability of these mutant molecules for therapy.  
 
Finally, for therapy, a proper drug delivery mode is needed to deliver these 
molecules, since high doses of these cytokines in circulation can be toxic and 
lead to serious side effects. For example, Ueki et al., (149) have shown that LIF 
protects the photoreceptors from oxidative stress induced by light damage. 
However, when delivered in large doses, it causes the unwanted side effect of 
lowering retinal function. Thus, for treatment of diseases like retinitis pigmentosa, 
a drug delivery mode which can deliver appropriate doses of IL-6 family 
cytokines in a sustained manner over long durations is highly desired. PEG 
hydrogels have been widely investigated for use in delivering a number of 
therapeutics in vivo. These hydrogels proved very biocompatible triggering 
minimal immune response. We have conducted studies and shown that the 
hydrogel properties can be effectively manipulated by varying the concentrations 
of macromer content. PEG hydrogels with 5000Da macromer size were found to 
be effective for delivering the cytokines over a period of 8 days in vivo. However, 
for treating the retinal degenerations, release rates over the order of months and 
years would be highly desirable. Manipulating the PEG macromer size might 
prove effective in attaining such release rates. Results also revealed that a 
release rate of at least 0.45 – 0.50 μg/day is required for hOSM to cross the 
choroid and RPE barriers to reach and induce STAT3 activation in retina. Thus,, 
further work in altering the molecular properties of hydrogels to obtain a steady 
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release rate of at least 0.5 μg/day OSM would prove very helpful in treating 
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∂                                                                         ------------ Eqn 1 
Where, C is the concentration of drug inside the gel at time t and position x, and 
Dg is the diffusion coefficient of the drug inside swollen hydrogel. The hydrogel is 
non-degradable and thus the structural properties of the hydrogel and thus 
diffusion coefficient of the drug will stay constant throughout the release process.  
 
Boundary Conditions: 
BC 1        ( ) 0, =± tLC
BC2                            ( ) oCxC =0, LxL +<<−  








Since, concentration (C) is a function of position (x) and time (t), assuming the 
variables are separable, C can be defined as; 
)( )( tGxFC =                                                                         ------------ Eqn 2 















∂                                                                     ------------ Eqn 3 
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On the left hand side, we have an expression dependent on ‘t’ while on the right 
hand side, we have an expression dependent on ‘x’. For them to be equal, both 


















                                                                         ------------ Eqn 5 
Solving equations 4 and 5 give, 
tDgeG
2λ−=                                                                               ------------ Eqn 6                       
xCosBxSinAF λλ     +=                                                            ------------ Eqn 7 
Thus, concentration (C) can be redefined as; 
( tDgexCosBxSinAC
2
   λλλ −+= )
)
                                                ------------ Eqn 8 
Since equation 1 is a linear equation, the most general solution is obtained by 











gnexCosBxSinAC λλλ                                       ------------ Eqn 9 





































xSinBxCosA λλ  
   0 (1)        =⇒ nA
 212
0       =⇒ nA  











gnexCosB λλ  
Since,  0at     0
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=≠− te tDgnλ
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Using boundary condition 2 in equation 9, 













π                  ------------ Eqn 10 




































Integrating with respect to ‘x’; 
































 -- Eqn 11 
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 L=                                               Since, ( ) 012 =+ πnSin  
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A2. Fractional Release of Drug as a function of time (t) 
 
Mass retained in the one-dimensional plane at time (t) = 0 is  LCo 2⋅






Mass retained at time (t) = ∞ is 0  
 
Thus, mass of the drug ( ) released in time, t is M(in pellet at t = 0) – M(in pellet 







−= ),(2  
Total mass of the drug that can be released ( ) is M(in pellet at t = 0)  ∞M



























































































































































































































































For any value of n;  
( ) ( ) 1
2





































Substituting this in equation 12, we obtain; 
 
( )
( )
⎥
⎥
⎦
⎤
⎢
⎢
⎣
⎡ +−
+
−= ∑
∞
=∞
2
22
0
22
t
4
12
exp
12
181
M
M
L
tnD
n
g
n
π
π  
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